Signpath Pharma S-1/A 27 Jan 15 2014 FY IPO registration (amended) Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Document and Entity Information
Entity Registrant Name	SIGNPATH PHARMA, INC.
Document Type	S-1
Document Period End Date	30-Sep-14
Amendment Flag	FALSE
Entity Central Index Key	1455694
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Entity Incorporation, State Country Name		Delaware
Entity Incorporation, Date of Incorporation		15-May-06

Balance_Sheets

Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
CURRENT ASSETS
Cash	$1,177,769	$1,241,397	$31,922
Total Current Assets	1,177,769	1,241,397	31,922
EQUIPMENT, net			144
TOTAL ASSETS	1,177,769	1,241,397	32,066
CURRENT LIABILITIES
Accounts payable and accrued expenses	874,631	421,632	894,475
Derivative liability			5,687,262
Total Current Liabilities	874,631	421,632	6,581,737
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred stock; $0.10 par value, 5,000,000 shares authorized 8,532 and 4,286 shares issued and outstanding, respectively	1,041	879	541
Common stock; $0.001 par value, 45,000,000 shares authorized; 12,877,500 and 12,837,500 shares issued and outstanding, respectively	14,125	12,879	12,839
Stock Payable	17,000
Accrued dividends	796,181	1,353,961	861,872
Additional paid-in capital	12,282,878	10,120,454	1,286,613
Deficit accumulated during the development stage	-12,808,087	-10,668,408	-8,711,536
Total Stockholders' Equity (Deficit)	303,138	819,765	-6,549,671
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$1,177,769	$1,241,397	$32,066

Balance_Sheets_Parenthetical

Balance Sheets Parenthetical (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Balance Sheets Parenthetical
Convertible preferred stock par value	$0.10	$0.10	$0.10
Convertible preferred stock shares authorized	5,000,000	5,000,000	5,000,000
Preferred stock shares issued	10,401	8,781	4,286
Preferred stock shares outstanding	10,401	8,781	4,286
Common stock par value	$0.00	$0.00	$0.00
Common stock shares authorized	45,000,000	45,000,000	45,000,000
Common stock shares issued	14,123,887	12,877,500	12,837,500
Common stock shares outstanding	14,123,887	12,877,500	12,837,500

Statements_of_Operations

Statements of Operations (USD $)	3 Months Ended		9 Months Ended		12 Months Ended		92 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Statements of Operations
REVENUES
OPERATING EXPENSES
General and administrative	45,582	9,613	60,041	23,433	53,957	45,596	1,303,596
Professional fees	88,204	82,482	320,176	777,947	808,865	121,586	1,784,218
Financing expense							1,063,401
Research and development	799,965	312,671	1,546,500	618,739	841,502	939,296	4,297,433
Salaries and wages	45,207	84,847	209,527	248,426	249,407	205,927	1,249,329
Total Operating Expenses	978,958	489,613	2,136,244	1,668,545	1,953,731	1,312,405	9,697,977
OPERATING LOSS	-978,958	-489,613	-2,136,244	-1,668,545	-1,953,731	-1,312,405	-9,697,977
OTHER INCOME (EXPENSE)
Gain (loss) on derivative liability			0	-3,926	-3,926	-8,154	-998,403
Gain on shares issued for services						9,625	9,625
Transaction loss	-4,003		-4,003
Grant income							81,556
Interest income	171	308	568	473	785		785
Interest expense							-63,995
Total Other Income (Expense)	-3,832	308	-3,435	-3,453	-3,141	1,471	-970,432
NET LOSS BEFORE INCOME TAXES	-982,790	-489,305	-2,136,679	-1,671,998	-1,956,872	-1,310,934	-10,668,408
Provision for income taxes
NET LOSS	-982,790	-489,305	-2,139,679	-1,671,998	-1,956,872	-1,310,934	-10,668,408
DEEMED DIVIDEND ON WARRANTS					-2,445,621		-2,445,621
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	($982,790)	($489,305)	($2,136,679)	($1,671,998)	($4,402,493)	($1,310,934)	($13,114,029)
BASIC AND DILUTED LOSS PER SHARE	($0.08)	($0.04)	($0.17)	($0.13)	($0.34)	($0.10)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING	12,877,500	12,858,599	12,877,500	12,848,108	12,877,500	12,833,258

Statements_of_Stockholders_Equ

Statements of Stockholders' Equity (USD $)	Preferred Stock	Common Stock	Accrued Dividends	Additional Paid in Capital	Deficit Accumulated During the Development Stage	Total
Balance at May. 15, 2006
Common stock issued to founders for cash at $0.001 per share		$10,000				$10,000
Common stock issued to founders for cash at $0.001 per share - shares		10,000,000
Balance at Dec. 31, 2006		10,000				10,000
Balance - shares at Dec. 31, 2006		10,000,000
Common stock issued for bridge debt at $0.85 per share		258		218,617		218,875
Common stock issued for bridge debt at $0.85 per share - shares		257,500
Net loss					-526,833	-526,833
Balance at Dec. 31, 2007		10,258		218,617	-526,833	-297,958
Balance - shares at Dec. 31, 2007		10,257,500
Preferred stock issued for bridge debt at $1,000 per share	89			889,786		889,875
Preferred stock issued for bridge debt at $1,000 per share - shares	890
Preferred stock issued for cash at $1,000 per share	56			561,944		562,000
Preferred stock issued for cash at $1,000 per share - shares	562
Common stock issued for bridge debt at $0.85 per share		1,083		919,043		920,126
Common stock issued for bridge debt at $0.85 per share - shares		1,082,500
Stock offering costs				-270,948		-270,948
Preferred dividend accrued			9,308	-9,308
Net loss					-1,695,766	-1,695,766
Balance at Dec. 31, 2008	145	11,341	9,308	2,309,134	-2,222,599	107,329
Balance - shares at Dec. 31, 2008	1,452	11,340,000
Preferred stock issued for cash at $1,000 per share	81			-178,632		-178,551
Preferred stock issued for cash at $1,000 per share - shares	810
Cumulative effect of adoption of ASC 815				-1,632,825	-43,808	-1,676,633
Stock offering costs				-166,154		-166,154
Preferred dividend accrued			124,576	-124,576
Net loss					-730,743	-730,743
Balance at Dec. 31, 2009	226	11,341	133,884	206,947	-2,997,150	-2,644,752
Balance - shares at Dec. 31, 2009	2,262	11,340,000
Preferred stock issued for cash at $1,000 per share	58			574,942		575,000
Preferred stock issued for cash at $1,000 per share - shares	575
Stock offering costs				-121,709		-121,709
Common stock issued for services		850		721,650		722,500
Common stock issued for services - shares		850,000
Amortization of options issued for services				39,210		39,210
Adjustment for derivative liability				-852,346		-852,346
Preferred dividend accrued			157,609	-157,609
Net loss					-2,119,059	-2,119,059
Balance at Dec. 31, 2010	284	12,191	291,493	411,085	-5,116,209	-4,401,156
Balance - shares at Dec. 31, 2010	2,837	12,190,000
Preferred stock issued for cash at $1,000 per share	145			1,448,355		1,448,500
Preferred stock issued for cash at $1,000 per share - shares	1,449
Stock offering costs				-267,966		-267,966
Common stock issued for services		640		543,360		544,000
Common stock issued for services - shares		640,000
Amortization of options issued for services				23,368		23,368
Adjustment for derivative liability				-917,263		-917,263
Preferred dividend accrued			219,082	-219,082
Net loss					-2,284,393	-2,284,393
Balance at Dec. 31, 2011	429	12,831	510,575	1,021,857	-7,400,602	-5,854,910
Balance - shares at Dec. 31, 2011	4,286	12,830,000
Preferred stock issued for cash	112			1,115,889		1,116,001
Preferred stock issued for cash - shares	1,116
Stock offering costs				-221,175		-221,175
Common stock issued for services		8		6,367		6,375
Common stock issued for services - shares		7,500
Amortization of options issued for services				16,772		16,772
Adjustment for derivative liability				-301,800		-301,800
Preferred dividend accrued			351,297	-351,297
Net loss					-1,310,934	-1,310,934
Balance at Dec. 31, 2012	541	12,839	861,872	1,286,613	-8,711,536	-6,549,671
Balance - shares at Dec. 31, 2012	5,402	12,837,500
Preferred stock issued for cash	338			3,379,662		3,380,000
Preferred stock issued for cash - shares	3,380
Stock offering costs				-550,326		-550,326
Common stock issued for services		40		33,960		34,000
Common stock issued for services - shares		40,000
Amortization of options issued for services				667,449		667,449
Executive forfeited salary				104,000		104,000
Adjustment for derivative liability				5,691,185		5,691,185
Preferred dividend accrued			492,089	-492,089
Net loss					-1,956,872	-1,956,872
Balance at Dec. 31, 2013	$879	$12,879	$1,353,961	$10,120,454	($10,668,408)	$819,765
Balance - shares at Dec. 31, 2013	8,782	12,877,500

STATEMENT_OF_STOCKHOLDERS_EQUI

STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical) (USD $)	8 Months Ended	12 Months Ended
	Dec. 31, 2006	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2007
STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical)
Common stock issued to founders for cash price per share	$0.00
Common stock issued for bridge debt price per share					$0.85	$0.85
Preferred Stock Issued for Bridge Debt per share price					$1,000
Preferred Stock Issued for cash per share price		$1,000	$1,000	$1,000	$1,000

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
OPERATING ACTIVITIES
Net loss	($2,139,679)	($1,671,998)	($1,956,872)	($1,310,934)
Adjustments to reconcile net loss to net cash used in operating activities:
Common stock issued for services	51,000	34,000	34,000	6,375
Options issued for services	186,384	650,025	667,449	16,772
Common stock issued with bridge financing	13,132
Depreciation expense		144	144	1,265
Change in derivative liability, net of bifurcation		3,926	3,926	8,154
Changes in operating assets and liabilities
Change in accounts payable and accrued expenses	452,999	-389,002	-368,846	395,040
Net Cash Used in Operating Activities	-1,436,164	-1,372,905	-1,620,199	-883,328
INVESTING ACTIVITIES
Purchase of equipment
Net Cash Used in Investing Activities
FINANCING ACTIVITIES
Preferred stock issued for cash	1,620,000	3,194,250	3,380,000	1,116,001
Stock offering costs paid	-247,464	-510,476	-550,326	-221,175
Common stock issued for cash		30,000
Proceeds from related party notes payable		-30,000	30,000
Proceeds from notes payable				55,075
Repayment of related party notes payable			-30,000
Repayment of notes payable				-55,075
Net Cash Provided by Financing Activities	1,372,536	2,683,774	2,829,674	894,826
NET INCREASE IN CASH	-63,628	1,310,869	1,209,475	11,498
CASH AT BEGINNING OF PERIOD	1,241,397	31,922	31,922	20,424
CASH AT END OF PERIOD	1,177,769	1,342,792	1,241,397	31,922
CASH PAID FOR:
Interest
Income taxes
NON CASH FINANCING ACTIVITIES:
Derivative liability non cash financing activity		-5,691,185		301,800
Executive forfeited salary			104,000
Common stock issued for dividends	1,025,404
Settlement of derivative liability			5,691,185
Preferred dividend accrual	$467,624	$349,939	$492,089	$351,298

Preferred_Stock

Preferred Stock (USD $)

12 Months Ended

92 Months Ended

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2008

Dec. 31, 2013

Nov. 25, 2008

Details

Convertible Preferred Stock Series B Issued

1,116

[1],[2],[3]

1,030

[1],[2],[3]

Convertible Preferred Stock Series A Issued

419

[1],[2],[4]

575

[1],[2],[4]

810

[1],[2],[4]

562

[1],[2],[4]

Convertible Preferred Stock issued for cash

890

[1],[2],[4]

Preferred stock issued for bridge financing

$889,875

Accrued dividends

$861,872

$1,353,961

[1]

par value $0.10

[2]

$1,000 per share

[3]

Series B

[4]

Series A

Common_Stock

Common Stock (USD $)	3 Months Ended				12 Months Ended
	Dec. 31, 2010		Sep. 30, 2010		Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Details
Stock Issued During Period, Shares, Issued for Services	450,000	[1]	400,000	[1]	40,000	[1]	7,500	[1]	640,000	[1]
Common stock issued for services					$34,000		$6,375		$544,000
Allocated Share-based Compensation Expense	382,500		340,000				16,000		289,000
Gain on shares issued for services							9,625
Salaries, Wages and Officers' Compensation									151,000
Extinguished accrued officer salary									$104,000
[1]	$0.85 per common share

NOTE_1

NOTE 1	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Notes
NOTE 1	NOTE 1 - CONDENSED FINANCIAL STATEMENTS	NOTE 1 – NATURE OF OPERATIONS
	The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at September 30, 2014, and for all periods presented herein, have been made.	SignPath Pharma, Inc., (the “Company”) was incorporated under the laws of the State of Delaware on May 15, 2006.  The Company was organized to develop proprietary formulations of curcumin (diferuloylmethane), a naturally occurring compound found in the root of the Curcuma longa (turmeric) plant, for applications in malignant diseases.  The Company’s product candidates are currently in the pre-clinical testing phase.
	Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company's December 31, 2013 audited financial statements. The results of operations for the period ended September 30, 2014 are not necessarily indicative of the operating results for the full year.

NOTE_2

NOTE 2	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Notes
NOTE 2	NOTE 2 - GOING CONCERN	NOTE 2 - GOING CONCERN
	The Company's financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and allow it to continue as a going concern. During the nine months ended September 30, 2014, the Company recognized sales revenue of $-0-~ and incurred a net loss of $2,139,679. As of September 30, 2014, the Company had an accumulated deficit of $12,808,087. The continuation of the Company as a going concern is dependent upon the continued financial support from its shareholders, the ability to raise equity or debt financing, and the attainment of profitable operations from the Company's planned business. If the Company is unable to obtain adequate capital, it could be forced to cease operations. These consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.	The Company's financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and allow it to continue as a going concern. During the year ended December 31, 2013, the Company recognized sales revenue of~ $-0- and incurred a net loss of $1,956,872.  As of December 31, 2013, the Company had an accumulated deficit of $10,668,408.  The continuation of the Company as a going concern is dependent upon the continued financial support from its shareholders, the ability to raise equity or debt financing, and the attainment of profitable operations from the Company's planned business. If the Company is unable to obtain adequate capital, it could be forced to cease operations. These consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
	In order to continue as a going concern, the Company will need, among other things, additional capital resources. Management's plan is to obtain such resources for the Company by obtaining capital from significant shareholders sufficient to meet its minimal operating expenses and seeking equity and/or debt financing. However management cannot provide any assurances that the Company will be successful in accomplishing any of its plans.	In order to continue as a going concern, the Company will need, among other things, additional capital resources. Management's plan is to obtain such resources for the Company by obtaining capital from significant shareholders sufficient to meet its minimal operating expenses and seeking equity and/or debt financing. However management cannot provide any assurances that the Company will be successful in accomplishing any of its plans.
	The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.	The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

NOTE_3

NOTE 3	9 Months Ended									12 Months Ended
	Sep. 30, 2014									Dec. 31, 2013
Notes
NOTE 3	NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES									NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Use of Estimates									Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.									The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
	Derivative Financial Instruments									Accounting Basis
	The Company generally does not use derivative financial instruments to hedge exposures to cash-flow risks or market-risks that may affect the fair values of its financial instruments. The Company utilizes various types of financing to fund our business needs, including preferred stock with warrants attached and other instruments not indexed to our stock. The Company is required to record its derivative instruments at their fair value. Changes in the fair value of derivatives are recognized in earnings in accordance with ASC 815.									The Company’s financial statements are prepared using the accrual basis of accounting in accordance with accounting principles generally accepted in the United States.  The Company has elected a December 31 fiscal year end.
	Fair Value of Financial Instruments									Cash and Cash Equivalents
	In accordance with ASC 820, the carrying value of cash and cash equivalents, accounts receivable and accounts payable approximates fair value due to the short-term maturity of these instruments. ASC 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:									The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. There were no cash equivalents as of December 31, 2013 or 2012.
	Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.									Concentration of Credit Risk
										Financial instruments, which potentially subject us to concentrations of credit risk, consist principally of cash.   Our cash balances are maintained in accounts held by major banks and financial institutions located in the United States.  The Company occasionally maintains amounts on deposit with a financial institution that are in excess of the federally insured limit of $250,000. The risk is managed by maintaining all deposits in high quality financial institutions. The Company had $991,397 and $0 of cash balances in excess of federally insured limits at December 31, 2013 and 2012, respectively.
	Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.
										Property and Equipment
	Level 3-Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.									Property and equipment is recorded at cost less accumulated depreciation. Depreciation and amortization is calculated using the straight-line method over the expected useful life of the asset, after the asset is placed in service. The Company generally uses the following depreciable lives for its major classifications of property and equipment:
	The carrying amounts reported in the balance sheets for cash, accounts payable and accrued expenses, approximate their fair market value based on the short-term maturity of these instruments. The following table presents assets and liabilities that are measured and recognized at fair value as of September 30, 2014, on a recurring basis:									Description		Useful Lives
										Computers		3 years
	Description	Level 1		Level 2		Level 3		Gains (Losses)		Equipment		5 years
		$	-	$	-	$	-	$	-	Fair Value of Financial Instruments
	Total	$	-	$	-	$	-	$	-	In accordance with ASC 820, the carrying value of cash and cash equivalents, accounts receivable and accounts payable approximates fair value due to the short-term maturity of these instruments.  ASC 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:
	The following table presents assets and liabilities that are measured and recognized at fair value as of December 31, 2013, on a recurring basis:									Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.
	Description	Level 1		Level 2		Level 3		Gains (Losses)		Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.
		$	-	$	-	$	-	$	-	Level 3-Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.
	Total	$	-	$	-	$	-	$	-
										The carrying amounts reported in the balance sheets for cash, accounts payable and accrued expenses approximate their fair market value based on the short-term maturity of these instruments. The following table presents assets and liabilities that are measured and recognized at fair value as of December 31, 2013, on a recurring basis:
	A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The following is a description of the valuation methodology used to measure fair value, as well as the general classification of such instruments pursuant to the valuation hierarchy.
										Description		Level 1		Level 2		Level 3		Total
	Recent Accounting Pronouncements									Derivative Liability		$	-	$	-	$	-	$	-
	The Company has evaluated recent accounting pronouncements and their adoption has not had nor is it expected to have a material impact on the Company’s financial position, or statements.									Total		$	-	$	-	$	-	$	-
	In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-10, “Development Stage Entities”. The amendments in this update remove the definition of a development stage entity from the Master Glossary of the ASC thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP.  In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had` been in the development stage. The amendments in this update are applied retrospectively. The early adoption of ASU 2014-10 is permitted which removed the development stage entity financial reporting requirements from the Company.									The following table presents assets and liabilities that are measured and recognized at fair value as of December 31, 2012, on a recurring basis:
										Description		Level 1		Level 2		Level 3		Total
										Derivative Liability		$	-	$	-	$	-5,687,262	$	-5,687,262
										Total		$	-	$	-	$	-5,687,262	$	-5,687,262
										A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The following is a description of the valuation methodology used to measure fair value, as well as the general classification of such instruments pursuant to the valuation hierarchy.
										Derivative Liability:     Market prices are not available for the Company's warrants nor are market prices of similar warrants available. The Company assessed that the fair value of this liability approximates its carrying value since carrying value has been adjusted to fair value.
										The method described above may produce a current fair value calculation that may not be indicative of net realizable value or reflective of future fair values. If a readily determined market value became available or if actual performance were to vary appreciably from assumptions used, assumptions may need to be adjusted, which could result in material differences from the recorded carrying amounts. The Company believes its method of determining fair value is appropriate and consistent with other market participants. However, the use of different methodologies or different assumptions to value certain financial instruments could result in a different estimate of fair value.
										The following tables present the fair value of financial instruments as of December 31, 2013, by caption on the condensed balance sheet and by ASC 820 valuation hierarchy described above.
											Stock Warrant
										Level 3 Reconciliation:	Derivative
										Level 3 assets and liabilities at December 31, 2012	$	-5,687,262
										Purchases, sales, issuances and settlements (net)		5,687,262
										Total level 3 assets and liabilities at December 31, 2013	$	-
										Derivative Financial Instruments
										The Company generally does not use derivative financial instruments to hedge exposures to cash-flow risks or market-risks that may affect the fair values of its financial instruments. The Company utilizes various types of financing to fund our business needs, including preferred stock with warrants attached and other instruments not indexed to our stock. The Company is required to record its derivative instruments at their fair value. Changes in the fair value of derivatives are recognized in earnings in accordance with ASC 815.
										Research and Development Costs
										The Company expenses the costs of the development of its pharmaceutical products during the period incurred. The Company incurred research and development expenses of $841,502 and $939,296 during the years ended December 31, 2013 and 2012, respectively.
										Stock-Based Compensation
										The Company follows the provisions of ASC 718 which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values.  The Company uses the Black-Scholes pricing model for determining the fair value of stock based compensation.
										Equity instruments issued to non-employees for goods or services are accounted for at fair value and are marked to market until service is complete or a performance commitment date is reached, whichever is earlier.
										Income Taxes
										The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.
										In July, 2006, the FASB issued ASC 740, Accounting for Uncertainty in Income Taxes, which clarifies the accounting for uncertainty in tax positions taken or expected to be taken in a return. ASC 740 provides guidance on the measurement, recognition, classification and disclosure of tax positions, along with accounting for the related interest and penalties. ASC 740 became effective as of January 1, 2007 and had no impact on the Company’s financial statements.
										The charge for taxation is based on the results for the year as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.
										Basic and Diluted Net income (Loss) per Share
										The Company computes net income (loss) per share in accordance with ASC 260 which requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive.
										For the years ended December 31, 2013 and 2012, all of the Company’s potentially dilutive securities (warrants, options, and convertible preferred stock) were excluded from the computation of diluted earnings per share as they were anti-dilutive.  The total number of potentially dilutive shares that were excluded was 18,162,608 and 12,814,874 at December 31, 2013 and 2012, respectively.
										Deemed Dividend on Warrant Amendment
										During the year ended December 31, 2013, the Company amended the terms of its Class A, B, C and PAW Warrants with certain investors who held warrants to purchase 11,364,453 shares of our common stock to extend the terms of the Warrants such that none of the Warrants expire before the 5th anniversary of the date on which the Common Stock begins public trading on a national securities exchange.   The modification of the expiration date of the warrant resulted in a deemed dividend to warrant holders of approximately, $2,445,621 which was calculated as the difference between fair value of the warrants immediately before and after the modification using the Black-Scholes option pricing model.  The deemed dividends have been included in the calculation of the net loss attributable to common stockholders of approximately $4,402,493 or $0.34 per share, the year ended December 31, 2013.  The deemed dividends are excluded from our net loss (from operating activities) of approximately $4,402,493, or $0.34 per share, for the year ended December 31, 2013.
										Recent Accounting Pronouncements
										The Company has evaluated recent accounting pronouncements and their adoption has not had nor is it expected to have a material impact on the Company’s financial position, or statements.

NOTE_4

NOTE 4	9 Months Ended							12 Months Ended
	Sep. 30, 2014							Dec. 31, 2013
Notes
NOTE 4	NOTE 4 – EQUIPMENT							NOTE 4 – EQUIPMENT
	Property and equipment consists of the following as of September 30, 2014 and December 31, 2013, respectively. Depreciation expense was $-0- for the nine months ended September 30, 2014 and December 31, 2013, respectively.							Property and equipment consists of the following as of December 31, 2013 and 2012. Depreciation expense was $144 and $1,265 for the years ended December 31, 2013 and 2012, respectively.
		September 30,			December 31,				2013		2012
		2014			2013			Computer equipment	$	5,390	$	5,390
								Accumulated Depreciation		-5,390		-5,246
	Computer equipment		$	5,390		$	5,390	Net Book Value	$	-	$	144
	Accumulated Depreciation			-5,390			-5,390
	Net Book Value		$	-		$	-

NOTE_5

NOTE 5	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Notes
NOTE 5	NOTE 5 – ACCRUED LIABILITIES	NOTE 5 – ACCRUED LIABILITIES
	Pursuant to the applicable Codification literature, the Company has concluded it is probable that it will pay $85,738 in liquidated damages pursuant to the registration rights clause in certain of the securities sold in fiscal years 2008 and 2009, the Company was required to file a registration statement by January 27, 2009. The Company failed to do so until April 7, 2009, resulting in liquidated damages of 2% per month of the gross proceeds, which approximated $1.8 million as of that date. During the year ended December 31, 2009, the Company’s registration statement covering the securities was declared effective by the SEC. Each holder is entitled to $47.32 per share owned. The Company has resolved to pay the liquidated damages in shares of Common Stock valued at $1.00 per share, pursuant to the terms and provisions of the Certificate of Designation, Preferences and Rights of Series A Convertible Preferred Stock.	Pursuant to the applicable Codification literature, the Company has concluded it is probable that it will pay $85,738 in liquidated damages pursuant to the registration rights clause in certain of the securities sold in fiscal years 2008 and 2009, the Company was required to file a registration statement by January 27, 2009. The Company failed to do so until April 7, 2009, resulting in liquidated damages of 2% per month of the gross proceeds, which approximated $1.8 million as of that date. During the year ended December 31, 2009, the Company’s registration statement covering the securities was declared effective by the SEC. Each holder is entitled to $47.32 per share owned. The Company has resolved to pay the liquidated damages in shares of Common Stock valued at $1.00 per share, pursuant to the terms and provisions of the Certificate of Designation, Preferences and Rights of Series A Convertible Preferred Stock.

NOTE_6

NOTE 6	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Notes
NOTE 6	NOTE 6 – NOTE PAYABLE	NOTE 6 – NOTE PAYABLE
	In January 2013, the Company received $25,000 in cash pursuant to a short-term promissory note with a related party. In March 2013, the Company received $5,000 in cash pursuant to a short-term promissory note with the same related party. The notes did not bear interest. The Company assessed the imputed interest and found the balance to be immaterial. In April 2013, the balance on the notes was repaid in full.	In January 2012, the Company received cash pursuant to a short-term promissory note with a related party. The note was repaid in full in February 2012. The note did not bear interest.
		On September 27, 2012, the Company received $55,075 in cash pursuant to a short-term promissory note with a related party. The note did not bear interest and was due on demand. In December 2012, the balance on the note was repaid in full.
		In January 2013, the Company received $25,000 in cash pursuant to a short-term promissory note with a related party. In March 2013 the Company received $5,000 in cash pursuant to a short-term promissory note with the same related party. The note did not bear interest.  The Company assessed the imputed interest and found the balance to be immaterial. In April 2013, the balance on the note was repaid in full.

NOTE_7

NOTE 7	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Notes
NOTE 7	NOTE 7 – DERIVATIVE LIABILITY AND FAIR VALUE MEASUREMENTS	NOTE 7 – DERIVATIVE LIABILITY AND FAIR VALUE MEASUREMENTS
	On May 7, 2013, the Company amended its Certificate of Incorporation to eliminate anti-dilution price protection from its Series A Preferred Stock and associated derivative liability. For the Nine-months ended September 30, 2014 and 2013, the Company incurred a change in fair value of derivative of $0 and $3,926, respectively.	The Company’s only asset or liability measured at fair value on a recurring basis is its derivative liability associated with its Series A Preferred Stock and associated warrants to purchase common stock.  On May 7, 2013, the Company amended its Certificate of Incorporation to eliminate anti-dilution price protection from its Series A Preferred Stock and associated derivative liability.  On January 1, 2009, the Company adopted ASC Topic No. 815-40 which defines determining whether an instrument (or embedded feature) is solely indexed to an entity’s own stock. As of January 1, 2009, the Company had issued 3,572,714 warrants which have exercise prices that are subject to “reset” provisions in the event the Company subsequently issues common stock, stock warrants, stock options or convertible debt with a stock price, exercise price or conversion price lower than $0.85 and $1.27, respectively. If these provisions are triggered, the exercise price of all of those warrants will be reduced.  As a result, the warrants are not considered to be solely indexed to the Company’s own stock and are not afforded equity treatment.
		As a result, on January 1, 2009, 3,572,714 of the Company’s outstanding warrants containing exercise price reset provisions, originally classified as permanent equity, were reclassified to derivative liability. These warrants had exercise prices ranging from $0.85 - $1.27 and expire starting in December 2013. As of January 1, 2009, the fair value of these warrants of $1,676,633 was recognized and resulted in a cumulative effect adjustment to retained earnings of $43,808. On May 7, 2013, the Company effectively removed the derivative provision from the warrants and convertible debt and valued the derivatives market to market as of that date. The derivative liability was then converted to additional paid-in-capital. The change in fair value during the years ended December 31, 2013 and 2012 of $(3,926) and $(8,154), respectively, is recorded as a derivative loss in the accompanying Statements of Operations.
		During the year ended December 31, 2012, the Company issued 1,313,533 warrants which were attached to 1,116 shares of convertible preferred stock. The Company issued an additional 757,223 warrants as stock offering costs to the Company’s placement agent. The combined fair market value of the derivative liability associated with these issuances at the date of issuance was $301,800.
		During the year ended December 31, 2011, the Company issued 1,704,884 warrants which were attached to 1,449 shares of convertible preferred stock.  The Company issued an additional 1,022,931 warrants as stock offering costs to the Company’s placement agent.  The combined fair market value of the derivative liability associated with these issuances at the date of issuance was $2,184,753.
		During the year ended December 31, 2010, the Company issued 676,775 warrants which were attached to 575 shares of convertible preferred stock.  The Company issued an additional 391,353 warrants as stock offering costs to the Company’s placement agent.  The Combined fair market value of the derivative liability associated with these issuances for the year ended December 31, 2010 was $852,346.
		During the year ended December 31, 2009, the Company issued 953,370 warrants which were attached to 810 shares of convertible preferred stock.  The Company issued an additional 286,011 warrants as stock offering costs to the Company’s placement agent.  The Combined fair market value of the derivative liability associated with these issuances for the year ended December 31, 2009 was $988,552.
		The Company classifies the fair value of these warrants under level three of the fair value hierarchy of financial instruments. The fair value of the derivative liability was calculated using a lattice model that values the compound embedded derivatives based on a probability weighted discounted cash flow model. This model is based on future projections of the various potential outcomes. The embedded derivatives that were analyzed and incorporated into the model included the conversion feature with the full ratchet reset, and the redemption options.
		The Series A Preferred Derivatives were valued using the following assumptions:
		·         The Company was 3 months from being publicly traded and the Company/Holder would convert the Preferred Stock based on 200% of the adjusted conversion price;
		·         The Preferred maturity date used was 7 years following the Company being publicly traded (rolling 6 years from the Valuation Date);
		·         The stock price of $0.85 was used as the fair value of the common stock based on the previous common stock transaction;
		·         The projected volatility curve was based on the average of 15 comparable biotech companies historical volatility:
		·         The Holder would automatically convert at a stock price of $1.70 if the Company was not in default;
		·         The Holder would convert on a quarterly basis in equal amounts to maturity if in the money; and
		·         Capital raising events would occur annually, generating reset events based on pricing not greater than 100% of market.
		The warrants were valued at issuance and marked to market quarterly for the period 2009 through December 2011. The five-year warrants are options to purchase shares of common stock at an exercise price of $0.85 per share and $1.27, subject to adjustments. The following assumptions were used for the valuation of the derivative:
		·         The stock price of $0.85 was used as the fair value of the common stock based on the previous common stock transaction;
		·         The projected volatility curve was based on the average of comparable companies as provided in the Preferred assumptions above;
		·         The Holder would exercise the warrant at maturity if the stock price was above the exercise price;
		·         The Holder would exercise the warrant at target prices starting at $1.58 for the Investor Warrants and $1.40 for the Placement Agent Warrants, and lowering such target as the warrants approached maturity.
		·         The Holder would automatically convert all of the shares at a stock price of $1.58 for the Investor Warrants and $1.40 for the Placement Agent Warrants;
		·         The Holder would convert on a quarterly basis in amounts not to exceed the average quarters trading volume based on historical performance, assuming the volume would increase by 5% each quarter; and
		·         Capital raising events would occur annually, generating reset events based on pricing not greater than 100% of market for the Placement Agent Warrants and for the Investor Warrants the reset would be 150% of the Preferred.
		The Company determined the fair value of the preferred stock to be $0 and $3,182,380 and the fair value of the warrants to be $0 and $2,504,879 at December, 2013 and December 31, 2012, respectively.
		The following shows the changes in the level three liability measured on a recurring basis from December 31, 2012 through December 31, 2013:
		Balance, December 31, 2012	$	5,687,262
		Derivative loss		3,923
		Derivative liability for warrants removed during the period		-5,691,185
		Balance, December 31, 2013	$	-

WARRANTS

WARRANTS	9 Months Ended					12 Months Ended
	Sep. 30, 2014					Dec. 31, 2013
Notes
WARRANTS	NOTE 10 – WARRANTS					NOTE 9 – WARRANTS
	A summary of the status of the Company's warrants as of September 30, 2014, and changes from December 31, 2013 through September 30, 2014 are presented below:					A summary of the status of the Company's warrants as of December 31, 2013 and changes from inception through December 31, 2012 are presented below:
	Date of	Warrant	Exercise		Value if	Date of	Warrant	Exercise	Value if
	Issuance	Shares	Price		Exercised	Issuance	Shares	Price	Exercised
	Outstanding at 12/31/13	12,792,728	1.18		15,065,087	11/25/08	1,259,639	1.27	$         1,599,742
	3/21/14	20,200	1.85		37,370	11/25/08	530,314	0.85	450,767
	3/21/14	50,000	1.85		92,500	11/26/08	449,220	1.27	570,509
	3/21/14	40,000	1.85		74,000	Outstanding at 12/31/2008	2,239,173	1.17	2,621,018
	3/21/14	40,000	1.85		74,000	3/5/09	347,215	1.27	440,963
	3/21/14	90,120	1.25		112,650	3/5/09	104,165	0.85	88,540
	5/5/14	4,000	1.88		7,520	4/1/09	17,655	1.27	22,422
	5/5/14	236,000	1.88		443,680	4/1/09	5,296	0.85	4,502
	5/5/14	144,000	1.25		180,000	6/17/09	235,400	1.27	298,958
	5/28/14	1,484,851	1.25		1,856,064	6/17/09	70,620	0.85	60,027
	5/28/14	(1,537,840)	1.25		(1,922,300)	7/23/09	58,850	1.27	74,740
	6/18/14	190,000	1.88		357,200	7/23/09	35,310	0.85	30,014
	6/18/14	16,000	1.88		30,080	8/20/09	58,850	1.27	74,740
	6/18/14	47,800	1.88		89,864	9/9/09	235,400	1.27	298,958
	6/18/14	4,000	1.88		7,520	9/9/09	70,620	0.85	60,027
	6/18/14	154,680	1.25		193,350	Outstanding at 12/31/2009	3,478,554	1.17	4,074,909
	7/22/14	(1,484,851)	1.25		(1,856,064)	2/11/10	29,425	1.27	37,370
	7/22/14	1,469,851	1.25		1,837,314	2/11/10	17,655	0.85	15,007
	7/22/14	15,000	1.25		18,750	5/21/10	29,425	1.27	37,370
	7/22/14	(607,200)	.85		(516,120)	5/21/10	17,655	0.85	15,007
	7/22/14	607,200	.85		516,120	8/10/10	88,275	1.27	112,109
	Outstanding at 9/30/14	13,776,539	1.43	$	19,673,118	8/10/10	52,965	0.85	45,020
						9/15/10	264,825	1.27	336,328
	As of December 1, 2013, the Company’s Board of Directors extended the terms of all outstanding warrants, some of which were set to expire in 2014 or 2015, such that none of the warrants expire before the fifth anniversary of the date on which the Company’s common stock begins trading on a national securities exchange, the OTC Bulletin Board for OTC Pink. The Company valued these warrants using the Black-Scholes option pricing model under the following assumptions: $0.85 and $1.27 stock price, $0.85 and $1.27 exercise price, the Warrants expire before the 5th anniversary of the date on which the Common Stock begins public trading, 107.73% volatility, .10% to 143% risk free rate.					9/15/10	52,965	0.85	45,020
						9/24/10	105,930	0.85	90,041
	During the period ended December 31, 2013, the Company extended the exercise period of 3,226,032 Class A warrants with an exercise price of $0.85 to expire on the fifth anniversary of the next registration statement to be filed. The Company valued these warrants using the Black-Scholes option pricing model under the following assumptions: $0.85 stock price, $0.85 exercise price, 5 to 7 years to maturity, 107% to 112% volatility, .96% to 2.26% risk free rate. As a result of the modification, the Company recognized a loss on equity modification of $156,477.					10/27/10	147,125	1.27	186,849
						10/27/10	73,563	0.85	62,529
	On February 20, 2013 the Company issued 400,000 warrants to its vendor for curcumin. The warrants have an exercise price of $0.85 per share and have a life of five years from the effective date of a registration statement.					11/19/10	117,700	1.27	149,479
						11/24/10	70,620	0.85	60,027
	During the period ended December 31, 2013, the Company issued 1,087,552 warrants as stock offering costs to the Company’s placement agent. The warrants were not deemed to be derivative instruments because they do not have a reset feature, and therefore no liability was booked related to the warrants.					Outstanding at 12/31/2010	4,546,682	1.16	5,267,063
						1/26/11	117,700	1.27	149,479
	The Company will issue cash or warrants as stock offering costs. The Company recognizes the cost upon completion of the share purchase. Warrants are valued and recorded using the lattice model. Total stock issuance costs for September 30, 2014 and 2013 were $247,464 and $404,151, respectively.					1/26/11	60,027	1.27	76,234
						1/26/11	106,636	0.85	90,641
	During the nine months ended September 30, 2014, the Company issued 403,800 warrants as stock offering costs to the Company’s placement agent. The warrants were not deemed to be derivative instruments because they do not have a reset feature, and therefore no liability was booked related to the warrants.					3/15/11	58,850	1.27	74,740
						3/15/11	35,310	0.85	30,014
	On July 22, 2014, the Company voided and replaced 2,092,051 placement agent warrants with an exercise price of $0.85 to $1.25 which will expire on the seventh anniversary of the modification. The Company valued these warrants using the Black-Scholes option pricing model under the following assumptions: $0.85 stock price, $0.85 exercise price, 5 to 7 years to maturity, 99.66% volatility, 1.91% to 2.13% risk free rate. As a result of the modification, the Company recognized a loss on equity modification of $13,132.					4/6/11	70,620	0.85	60,027
						4/6/11	117,700	1.27	149,479
	The holders of the Series C Preferred Stock are entitled to receive annual cumulative per share dividends of 6.5% and a liquidation preference, out of funds legally available, prior to any payment of dividends on the Company’s common stock or any other class of stock ranking junior to the Series C Preferred Stock but junior to the Series A Preferred Stock. Such dividends are payable in cash or shares of common stock, at the option of the Company. The holders of the Series C Preferred Stock are entitled to share ratably with the holders of the common stock in any dividend declared on the common stock.					6/8/11	51,200	0.85	43,520
						6/8/11	85,333	1.27	108,373
	Dividends on the Series C Preferred Stock will accrue whether or not the Company has earnings, whether or not there are funds legally available for the payment of such dividends and whether or not such dividends are declared. Dividends accumulate to the extent they are not paid on the Dividend Payment Date to which they relate. According to Delaware law, the Company may declare and pay dividends or make other distributions on its capital stock only out of legally-available funds. In addition, no dividends or distributions may be declared, paid or made if the Company is or would be rendered insolvent by virtue of such dividend or distribution. The Company may not (i) pay any dividends in respect of any shares of capital stock ranking junior to the Series C Preferred Stock (including the common stock), other than dividends payable in the form of additional shares of the same junior stock as that on which such dividend is declared, or (ii) redeem any shares of capital stock ranking junior to the Series C Preferred Stock (including the common stock), unless and until all accumulated and unpaid dividends on the Series C Preferred Stock have been, or contemporaneously are, declared and paid in full.					6/20/11	17,655	0.85	15,007
						6/20/11	29,425	1.27	37,370
	The Company’s balance, for dividends payable, as of September 30, 2014 and December 31, 2013 is, $796,181 and $1,353,961, respectively.					7/26/11	23,540	1.27	29,896
						7/26/11	14,124	0.85	12,005
						8/22/11	29,424	1.27	37,368
						8/22/11	17,655	0.85	15,007
						8/30/11	105,930	0.85	90,041
						9/2/11	176,550	1.27	224,219
						9/9/11	58,850	1.27	74,740
						9/9/11	35,310	0.85	30,014
						9/22/11	441,375	1.27	560,546
						9/22/11	264,825	0.85	225,101
						11/2/11	141,240	0.85	120,054
						11/2/11	235,400	1.27	298,958
						11/23/11	35,310	0.85	30,014
						11/23/11	58,850	1.27	74,740
						12/27/11	127,116	0.85	108,049
						12/27/11	211,860	1.27	269,062
						Outstanding at 12/31/11	7,274,497	1.14	8,301,757
						1/31/12	117,700	1.27	149,479
						1/31/12	70,620	0.85	60,027
					2/2/12	76,505	1.27	97,161
					2/2/12	45,903	0.85	39,018
					2/10/12	58,850	1.27	74,740
					2/10/12	35,310	0.85	30,014
					4/10/12	41,666	0.85	35,416
					4/10/12	69,443	1.27	88,193
					5/11/12	35,310	0.85	30,014
					5/11/12	58,850	1.27	74,740
					6/4/12	35,310	0.85	30,014
					6/4/12	58,850	1.27	74,740
					6/19/12	35,310	0.85	30,014
					6/19/12	58,850	1.27	74,740
					7/24/12	44,138	1.27	56,055
					7/24/12	58,850	1.27	74,740
					7/24/12	30,896	0.85	26,262
					7/30/12	235,400	1.27	298,958
					7/30/12	141,240	0.85	120,054
					8/28/12	258,352	1.27	328,107
					8/28/12	155,011	0.85	131,759
					10/18/12	158,895	1.27	201,797
					10/18/12	95,337	0.85	81,036
					11/26/12	58,850	1.27	74,740
					11/27/12	35,310	0.85	30,014
					Outstanding at 12/31/12	9,345,253	1.14	10,613,584
					2/28/13	400,000	0.85	340,000
					3/1/13	(1,625,192)	0.85	(1,381,413)
					3/1/13	1,625,192	0.85	1,381,413
					3/13/13	800,000	1.88	1,500,000
					3/13/13	480,000	0.85	408,000
					6/19/13	127,200	0.85	108,120
					6/19/13	212,000	1.88	397,500
					7/24/13	60,000	1.88	112,500
					7/24/13	100,000	1.88	187,500
					7/24/13	96,000	1.25	120,000
					8/29/13	80,000	1.88	150,000
					8/29/13	48,000	1.25	60,000
					8/29/13	(48,000)	1.25	(60,000)
					10/24/13	61,764	0.85	52,499
					10/24/13	10,588	0.85	9,000
					10/24/13	1,552,840	0.85	1,319,914
					10/24/13	(1,552,840)	0.85	(1,319,914)
					10/24/13	10,000	1.25	12,500
					10/24/13	38,000	1.25	47,500
					11/8/13	100,000	1.88	187,500
					11/8/13	60,000	1.25	75,000
					12/18/13	78,000	1.25	97,500
					12/18/13	78,000	1.25	97,500
					12/18/13	15,000	0.85	12,750
					12/18/13	1,537,840	0.85	1,307,164
					Outstanding at 12/31/13	13,689,648	1.13	15,849,164
					The warrants were issued in connection with the Preferred Stock Offering and were valued using the Lattice model and accounted for as described in Note 9.
					As of December 1, 2013, the Company’s Board of Directors extended the terms of all outstanding warrants, some of which were set to expire in 2014 or 2015, such that none of the warrants expire before the fifth anniversary of the date on which the Company’s common stock begins trading on a national securities exchange, the OTC Bulletin Board or OTC Pink. The Company valued these warrants using the Black-Scholes option pricing model under the following assumptions: $0.85 and $1.27 stock price, $0.85 and $1.27 exercise price, the Warrants expire before the 5th anniversary of the date on which the Common Stock begins public trading on a national securities exchange, 107.73% volatility, .10% to 1.43% risk free rate.
					During the period ended December 31, 2013, the Company extended the exercise period of 3,226,032 Class A warrants with an exercise prices of $0.85 to expire on the fifth anniversary of the next registration statement to be filed. The Company valued these warrants using the Black-Scholes option pricing model under the following assumptions: $0.85 stock price, $0.85 exercise price, 5 to 7 years to maturity, 107% to 112% volatility, .96% to 2.26% risk free rate.  As a result of the modification the Company recognized a loss on equity modification of $156,477.
					On February 20, 2013, the Company issued 400,000 warrants to its vendor for curcumin. The warrants have an exercise price of $0.85 per share and have a life of five years from the effective date of a registration statement.  The Company valued these warrants using the Black-Scholes option pricing model under the following assumptions: $0.85 stock price, $0.85 exercise price, 5 years to maturity, 885% volatility, .85% risk free rate. The Company recorded expense of $339,997 related to these warrants for the year ended December 31, 2013.
					During the period ended December 31, 2013, the Company issued 1,087,552 warrants as stock offering costs to the Company’s placement agent. The warrants were not deemed to be derivative instruments because they do not have a reset feature, and therefore no liability was booked related to the warrants.
					The Company will issue cash or warrants as stock offering costs.  The Company recognizes the cost upon completion of the share purchase.  Warrants are valued and recorded using the lattice model.  Total stock issuance costs for December 31, 2013 and 2012 were $550,326 and $221,175, respectively.
					The holders of the Series C Preferred Stock are entitled to receive annual cumulative per share dividends of 6.5% and a liquidation preference, out of funds legally available, prior to any payment of dividends on the Company’s common stock or any other class of stock ranking junior to the Series C Preferred Stock but junior to the Series A Preferred Stock. Such dividends are payable in cash or shares of common stock, at the option of the Company. The holders of the Series C Preferred Stock are entitled to share ratably with the holders of the common stock in any dividend declared on the common stock.
					Dividends on the Series C Preferred Stock will accrue whether or not the Company has earnings, whether or not there are funds legally available for the payment of such dividends and whether or not such dividends are declared. Dividends accumulate to the extent they are not paid on the Dividend Payment Date to which they relate. According to Delaware law, the Company may declare and pay dividends or make other distributions on its capital stock only out of legally-available funds. In addition, no dividends or distributions may be declared, paid or made if the Company is or would be rendered insolvent by virtue of such dividend or distribution. The Company may not (i) pay any dividends in respect of any shares of capital stock ranking junior to the Series C Preferred Stock (including the common stock), other than dividends payable in the form of additional shares of the same junior stock as that on which such dividend is declared, or (ii) redeem any shares of capital stock ranking junior to the Series B Preferred Stock (including the common stock), unless and until all accumulated and unpaid dividends on the Series C Preferred Stock have been, or contemporaneously are, declared and paid in full.
					The Company’s balance, for dividends payable, as of December 31, 2013 and 2012 is, $1,353,961 and $861,872, respectively.

STOCK_OPTIONS

STOCK OPTIONS	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Notes
STOCK OPTIONS	NOTE 11 – STOCK OPTIONS	NOTE 10 – STOCK OPTIONS
	The Company’s 2009 Employee Stock Incentive Plan (the “2009 Plan”) was adapted by the Company’s Board of Directors on February 9, 2009 in order to motivate participants by means of stock options and restricted stock to achieve the Company’s long-term performance goals and enable our employees, officers, directors and consultants to participate in our long term growth and financial success. The 2009 Plan, which is administered by our Board of Directors, currently authorizes the issuance of a maximum of 1,047,000 (as of January 1, 2014) shares of our common stock, which may be authorized and unissued shares or treasury shares. On February 13, 2013, the Board of Directors authorized an amendment to the 2009 Plan to increase the number of authorized options and shares to 1,000,000 plus on a yearly basis by 10% of the amount of shares issued during the prior year. Employee options shall be deemed Incentive Stock Options (as defined in the 2009 Option Plan) to the maximum extent permitted by Section 422 of the Internal Revenue Code including a five-year limit on exercise for 10% or greater stockholders with any excess grant to the above individuals over the limits set by Section 422 being Non-Qualified Stock Options as defined in the 2009 Option Plan. Both the Incentive Stock Options or any Non-Qualified Stock Options must be granted at an exercise price of not less than the fair market value of shares of common stock at the time the option is granted and Incentive Stock Options granted to 10% or greater stockholders must be granted at an exercise price of not less than 110% of the fair market value of the shares on the date of grant.	The Company’s 2009 Employee Stock Incentive Plan (the “2009 Plan”) was adapted by the Company’s Board of Directors on February 9, 2009 in order to motivate participants by means of stock options and restricted stock to achieve the Company’s long-term performance goals and enable our employees, officers, directors and consultants to participate in our long term growth and financial success. The 2009 Plan, as amended on February 13, 2013, which is administered by our Board of Directors, authorizes the issuance of a maximum of 1,000,000 shares of our common stock, plus on a yearly basis an additional amount equal to 10% of the amount of shares issued during the prior year.  Thus, as of January 1, 2014, a maximum of 1,047,000 shares were authorized for issuance under the 2009 Plan.  Employee options shall be deemed Incentive Stock Options (as defined in the 2009 Option Plan) to the maximum extent permitted by Section 422 of the Internal Revenue Code including a five-year limit on exercise for 10% or greater stockholders with any excess grant to the above individuals over the limits set by Section 422 being Non-Qualified Stock Options as defined in the 2009 Option Plan. Both the Incentive Stock Options or any Non-Qualified Stock Options must be granted at an exercise price of not less than the fair market value of shares of common stock at the time the option is granted and Incentive Stock Options granted to 10% or greater stockholders must be granted at an exercise price of not less than 110% of the fair market value of the shares on the date of grant.
	If any award under the 2009 Plan terminates, expires unexercised, or is cancelled, the shares of common stock that would otherwise have been issuable pursuant thereto will be available for issuance pursuant to the grant of new awards. The 2009 Plan will terminate on February 9, 2019. As of September 30, 2014, an aggregate of 830,000 options had been granted under the plan, as follows:	If any award under the 2009 Plan terminates, expires unexercised, or is cancelled, the shares of common stock that would otherwise have been issuable pursuant thereto will be available for issuance pursuant to the grant of new awards. The 2009 Plan will terminate on February 9, 2019. As of December 31, 2013, the following options had been granted under the plan:
	1On February 20, 2013 the Company issued 60,000 options to a member of its board of directors under the 2009 plan for compensation during 2013. The options have an exercise price of $1.25 per share and have a life of five years. The options vest as follows: one fourth on the date of grant, one fourth on every quarter from grant date. The Company valued these options using the Black-Scholes option pricing model totaling $51,000 under the following assumptions: $0.85 stock price, $1.25 exercise price, 5 years to maturity, 649% volatility, .35% risk free rate. As of December 31, 2013, these options were fully vested and expensed.	1On July 12, 2010 the Company issued 100,000 options to a member of its board of directors under the 2009 plan. The options have an exercise price of $0.85 per share and have a life of ten years. The options vest as follows: one third on the date of grant, one third on each of the second and third anniversary dates from the date of grant. The Company valued these options using the Black-Scholes option pricing model totaling $84,300 under the following assumptions: $0.85 stock price, $0.85 stock price, 10 years to maturity, 400% volatility, 2.02% risk free rate.  The Company recorded amortization expense of $4,952 and $16,772 related to these options for the years ended December 31, 2013 and 2011.
	2On February 20, 2013 the Company issued 60,000 options to a member of its board of directors under the 2009 plan for compensation during 2012. The options have an exercise price of $0.85 per share and have a life of five years. The options vest as follows: one fourth on the date of grant, one fourth on every quarter from grant date. The Company valued these options using the Black-Scholes option pricing model totaling $51,000 under the following assumptions: $0.85 stock price, $1.25 exercise price, 5 years to maturity, 649% volatility, .35% risk free rate. As of December 31, 2013, these options were fully vested and expensed.	2On February 20, 2013 the Company issued 60,000 options to a member of its board of directors under the 2009 plan for services to be rendered during 2013. The options have an exercise price of $1.25 per share and have a life of five years. The options vest as follows: one fourth on the date of grant, one fourth on every quarter from grant date. The Company valued these options using the Black-Scholes option pricing model totaling $51,000 under the following assumptions: $0.85 stock price, $1.25 exercise price, 5 years to maturity, 649% volatility, .35% risk free rate.  The Company recorded amortization expense of $50,928 related to these options for the year ended December 31, 2013.
	3On February 20, 2013 the Company issued 60,000 options to a member of its board of directors under the 2009 plan for compensation during 2013. The options have an exercise price of $1.25 per share and have a life of five years. The options vest as follows: one fourth on the date of grant, one fourth on every quarter from grant date. The Company valued these options using the Black-Scholes option pricing model totaling $51,000 under the following assumptions: $0.85 stock price, $1.25 exercise price, 5 years to maturity, 649% volatility, .35% risk free rate. As of December 31, 2013, these options were fully vested and expensed.	3On February 20, 2013 the Company issued 60,000 options to a member of its board of directors under the 2009 plan for services rendered during 2012. The options have an exercise price of $0.85 per share and have a life of five years. The options vest as follows: one fourth on the date of grant, one fourth on every quarter from grant date. The Company valued these options using the Black-Scholes option pricing model totaling $51,000 under the following assumptions: $0.85 stock price, $0.85 exercise price, 5 years to maturity, 649% volatility, .35% risk free rate. The Company recorded amortization expense of $50,941 related to these options for the year ended December 31, 2013.
	4On February 20, 2013 the Company issued 60,000 options to a member of its board of directors under the 2009 plan for compensation during 2012. The options have an exercise price of $0.85 per share and have a life of five years. The options vest as follows: one fourth on the date of grant, one fourth on every quarter from grant date. The Company valued these options using the Black-Scholes option pricing model totaling $51,000 under the following assumptions: $0.85 stock price, $1.25 exercise price, 5 years to maturity, 649% volatility, .35% risk free rate. As of December 31, 2013, these options were fully vested and expensed.	4On February 20, 2013 the Company issued 60,000 options to a member of its board of directors under the 2009 plan for services to be rendered during 2013. The options have an exercise price of $1.25 per share and have a life of five years. The options vest as follows: one fourth on the date of grant, one fourth on every quarter from grant date. The Company valued these options using the Black-Scholes option pricing model totaling $51,000 under the following assumptions: $0.85 stock price, $1.25 exercise price, 5 years to maturity, 649% volatility, .35% risk free rate. The Company recorded amortization expense of $50,928 related to these options for the year ended December 31, 2013.
	5On February 20, 2013 the Company issued 82,400 options to its CEO and a member of its board of directors under the 2009 plan. The options have an exercise price of $0.85 per share and have a life of five years. The options vest as follows: one fourth on the date of grant, one fourth on every quarter from grant date. The Company valued these options using the Black-Scholes option pricing model under the following assumptions: $0.85 stock price, $0.85 exercise price, 5 years to maturity, 626% volatility, .35% risk free rate.	5On February 20, 2013 the Company issued 60,000 options to a member of its board of directors under the 2009 plan for services rendered during 2012. The options have an exercise price of $0.85 per share and have a life of five years. The options vest as follows: one fourth on the date of grant, one fourth on every quarter from grant date. The Company valued these options using the Black-Scholes option pricing model totaling $51,000 under the following assumptions: $0.85 stock price, $0.85 exercise price, 5 years to maturity, 649% volatility, .35% risk free rate. The Company recorded amortization expense of $50,928 related to these options for the year ended December 31, 2013.
	6On February 20, 2013 the Company issued 117,600 options to its CEO and a member of its board of directors under the 2009 plan. The options have an exercise price of $0.85 per share and have a life of five years. The options vest as follows: one fourth on the date of grant, one fourth on every quarter from grant date. The Company valued these options using the Black-Scholes option pricing model totaling $70,040 under the following assumptions: $0.85 stock price, $0.85 exercise price, 5 years to maturity, 626% volatility, .35% risk free rate. As of December 31, 2013, these options were fully vested and expensed.	6On February 20, 2013 the Company issued 82,400 incentive stock options to its CEO and a member of its board of directors under the 2009 plan. The options have an exercise price of $0.85 per share and have a life of five years. The options vest as follows: one fourth on the date of grant, one fourth on every quarter from grant date. The Company valued these options using the Black-Scholes option pricing model totaling $70,040 under the following assumptions: $0.85 stock price, $0.85 exercise price, 5 years to maturity, 626% volatility, .35% risk free rate. The Company recorded amortization expense of $69,918 related to these options for the year ended December 31, 2013.
	7On February 20, 2013 the Company issued 30,000 options to its law firm under the 2009 Plan. The options have an exercise price of $0.85 per share and have a life of five years. The options vest as follows: one fourth on the date of grant, one fourth on every quarter from grant date. The Company valued these options using the Black-Scholes option pricing model totaling $25,500 under the following assumptions: $0.85 stock price, $0.85 exercise price, 5 years to maturity, 885% volatility, .88% risk free rate. As of December 31, 2013, these options were fully vested and expensed.	7On February 20, 2013 the Company issued 117,600 options to its CEO and a member of its board of directors under the 2009 plan. The options have an exercise price of $0.85 per share and have a life of five years. The options vest as follows: one fourth on the date of grant, one fourth on every quarter from grant date. The Company valued these options using the Black-Scholes option pricing model totaling $99,960 under the following assumptions: $0.85 stock price, $0.85 exercise price, 5 years to maturity, 626% volatility, .35% risk free rate. The Company recorded amortization expense of $99,786 related to these options for the year ended December 31, 2013.
	8On May 1, 2014, the Company issued 30,000 options to a member of its board of directors under the 2009 plan for compensation during 2014. The options have an exercise price of $1.25 per share and have a life of five years. The options vest as follows: one fourth on the date of grant, one fourth on every quarter from grant date. The Company valued these options using the Black-Scholes option pricing model totaling $21,613 under the following assumptions: $0.85 stock price, $1.25 exercise price, 5 years to maturity, 305% volatility, .64% risk free rate. As of September 30, 2014, $10,806 were expensed.	8On February 20, 2013 the Company issued 30,000 options to its law firm under the 2009 Plan. The options have an exercise price of $0.85 per share and have a life of five years. The options vest as follows: one fourth on the date of grant, one fourth on every quarter from grant date. The Company valued these options using the Black-Scholes option pricing model totaling $25,500 under the following assumptions: $0.85 stock price, $0.85 exercise price, 5 years to maturity, 885% volatility, .88% risk free rate. The Company recorded amortization expense of $25,471 related to these options for the year ended December 31, 2013.
	9On May 1, 2014, the Company issued 30,000 options to a member of its board of directors under the 2009 plan for compensation during 2014. The options have an exercise price of $1.25 per share and have a life of five years. The options vest as follows: one fourth on the date of grant, one fourth on every quarter from grant date. The Company valued these options using the Black-Scholes option pricing model totaling $21,613 under the following assumptions: $0.85 stock price, $1.25 exercise price, 5 years to maturity, 305% volatility, .64% risk free rate. As of September 30, 2014, $10,806 were expensed.	The Company has recorded amortization expense of $667,449 and $16,772 related to these options for the year ended December 31, 2013 and 2012.
	10On May 1, 2014, the Company issued 200,000 options to its CEO and a member of its board of directors under the 2009 plan. The options have an exercise price of $0.85 per share and have a life of five years. The options vest immediately on grant date. The Company valued these options using the Black-Scholes option pricing model totaling $162,580 under the following assumptions: $0.85 stock price, $1.25 exercise price, 5 years to maturity, 415.87% volatility, 1.66% risk free rate.. As of September 30, 2014 the option issued were fully expensed.
	The Company has recorded amortization expense of $186,385 and $650,025 related to these options for the nine months ended September 30, 2014 and 2013.

NOTE_11

NOTE 11	12 Months Ended
	Dec. 31, 2013
Notes
NOTE 11	NOTE 11 – INCOME TAXES
	The Company’s provision for income taxes was $0 for the years ended December 31, 2013 and 2012 respectively since the Company incurred net operating losses which have a full valuation allowance through December 31, 2012.
	ASC 740 requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. In the Company’s opinion, it is uncertain whether they will generate sufficient taxable income in the future to fully utilize the net deferred tax asset. Accordingly, a full valuation allowance equal to the deferred tax asset has been recorded. The total deferred tax asset is calculated by multiplying a 39% marginal tax rate by the cumulative Net Operating Loss (“NOL”) of $7,436,707. The total valuation allowance is equal to the total deferred tax asset.  The valuation allowance increased by $488,084 from $2,412,232 to $2,900,316 for the year ended December 31, 2013.
	The tax effects of significant items comprising the Company's net deferred taxes as of December 31, 2013 and 2012 were as follows:
		2013		2012
	Cumulative NOL	$	7,436,707	$	6,185,210
	Deferred Tax assets:
	Net operating loss carry forwards		2,900,316		2,412,232
	Valuation allowance		-2,900,316		-2,412,232
		$	-	$	-
	The income tax provision differs from the amount of income tax determined by applying the U.S. federal and state income tax rates of 39% to pretax income from continuing operations for the years ended December 31, 2013 and 2012 due to the following:
		2013		2012
	Income tax benefit at U. S. federal statutory rates:	$	-763,180	$	-511,264
	Stock-based compensation		273,565		9,027
	Derivative liability		1,531		3,180
	Change in valuation allowance		488,084		499,057
		$	-	$	-
	The Company adopted the provisions of ASC 740 at the beginning of fiscal year 2008. As a result of this adoption, the Company has not made any adjustments to deferred tax assets or liabilities.  The Company did not identify any material uncertain tax positions on returns that have been filed or that will be filed.  The Company did not recognize any interest or penalties for unrecognized tax benefits during the years ended December 31, 2013 and 2012, nor were any interest or penalties accrued as of December 31, 2013.
	The Company has filed income tax returns in the United States and Florida. All tax years prior to 2009 are closed by expiration of the statute of limitations.   The years ended December 31, 2013, 2012, and 2011 is open for examination.
	The Company’s net state and federal operating loss carry forwards of approximately $7,436,707 expire in various years beginning in 2027 and carrying forward through 2033.
	The Company has had numerous transactions in its common stock.  Such transactions may have resulted in a change in the Company's ownership, as defined in the Internal Revenue Code Section 382.  Such change may result in an annual limitation on the amount of the Company's taxable income that may be offset with its net operating loss carry forwards.  The Company has not evaluated the impact of Section 382, if any, on its ability to utilize its net operating loss carry forwards in future years.

NOTE_12

NOTE 12	12 Months Ended
	Dec. 31, 2013
Notes
NOTE 12	NOTE 12 – RELATED PARTY TRANSACTIONS
	On January 31, 2013, the Company signed a demand promissory note with a related party. The principal sum of the note was $25,000, bearing no interest.
	On March 4, 2013, the Company signed a demand promissory note with a related party. The principal sum of the note was $5,000, bearing no interest.
	On March 1, 2013, the Company paid the principal sum of $30,000 on demand promissory notes

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Notes
SUBSEQUENT EVENTS	NOTE 12 – SUBSEQUENT EVENTS	NOTE 13 – SUBSEQUENT EVENTS
	In accordance with ASC 855-10 Company management reviewed all material events through the date of this report and had no material subsequent events.	In accordance with ASC 855-10 Company management reviewed all material events through the date of this report and had no material subsequent events to report.

NOTE_8

NOTE 8	9 Months Ended
	Sep. 30, 2014
Notes
NOTE 8	NOTE 8 – PREFERRED STOCK
	Series A Convertible Preferred Stock
	The Series A Convertible Preferred Stock (“Preferred Stock”) has been authorized by resolutions adopted by the Company’s Board of Directors and set forth in a Certificate of Designation, Preferences and Rights (“Certificate of Designation”), filed with the Secretary of State of Delaware on November 26, 2008, as last amended on July 17, 2013, which contains the designations, rights, powers, preferences, qualifications and limitations of the Series A Preferred Stock. The shares of Preferred Stock are fully paid and non-assessable. As of September 30, 2014, the Company has issued 3,255 shares of Series A Preferred Stock convertible into an aggregate of approximately 3,831,576 shares of common stock.
	Rank
	The Preferred Stock ranks(i) senior to the common stock and any other class or series of the Company’s capital stock either specifically ranking by its terms junior to the Preferred Stock or not specifically ranking by its terms senior to or on parity with the Preferred Stock, (ii) on parity with any class or series of the Company’s capital stock specifically ranking by its terms on parity with the Preferred Stock, and (iii) junior to any class or series of capital stock specifically ranking by its terms senior to the Preferred Stock, in each case, as to payment of dividends or as to distributions of assets upon liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary. The approval of the holders of a majority of the Preferred Stock is required in order for the Company to issue any capital stock with rights on parity with or senior to the Preferred Stock.
	Dividends
	The holders of the Preferred Stock are entitled to receive annual cumulative per share dividends of 6.5% of the liquidation preference of the Preferred Stock, out of funds legally available, prior to any payment of dividends on the Company’s common stock or any other class of stock ranking junior to the Preferred Stock. Such dividends are payable in cash or shares of common stock, at the option of the Company, semiannually on the last business day of February and August of each year (each a “Dividend Payment Date”), commencing in February 2009 with respect to the period from issuance through such date. In September 2014, the Company issued 1,206,387 shares of common stock for accrued dividends. As of September 30, 2014, an aggregate of 796,181 shares of common stock are issuable for accrued dividends. The holders of the Preferred Stock are entitled to share ratably with the holders of the common stock in any dividend declared on the common stock.
	Dividends on the Preferred Stock will accrue whether or not the Company has earnings, whether or not there are funds legally available for the payment of such dividends and whether or not such dividends are declared. Dividends accumulate to the extent they are not paid on the Dividend Payment Date to which they relate. Dividends that are due in cash and which are not paid within (5) business days of the Dividend Payment date shall bear interest until paid at the default rate. According to Delaware law, the Company may declare and pay dividends or make other distributions on its capital stock only out of legally-available funds. In addition, no dividends or distributions may be declared, paid or made if the Company is or would be rendered insolvent by virtue of such dividend or distribution. The Company may not (i) pay any dividends in respect of any shares of capital stock ranking junior to the Preferred Stock (including the common stock), other than dividends payable in the form of additional shares of the same junior stock as that on which such dividend is declared, or (ii) redeem any shares of capital stock ranking junior to the Preferred Stock (including the common stock), unless and until all accumulated and unpaid dividends on the Preferred Stock have been, or contemporaneously are, declared and paid in full.
	Conversion
	At the election of the holder thereof, each share of Preferred Stock will be convertible into common stock, at any time after issuance, at the Conversion Rate, as it may be adjusted from time to time in accordance with the Certificate of Designation. The Conversion Rate initially will be 1,177 shares of common stock ($.85 per share) for each Share of Preferred Stock, which has a stated value of $1,000 per share. If the Company issues or sells any shares of its common stock (or options, warrants or convertible securities, convertible or exchangeable into shares of common stock) hereinafter, a “Subsequent common stock Issuance”), then the Conversion Rate will be adjusted so that the number of shares of common stock issuable upon conversion of each share of preferred stock shall be equal to the quotient obtained by dividing $1,000 by the price per share of common stock (or the conversion price per share in the case of a sale of options, warrants or convertible securities) sold in such Subsequent common stock Issuance.
	The Conversion Price is also subject to adjustment from time to time in the event of (i) the issuance of common stock as a dividend or distribution on any class of the Company’s capital stock; or (ii) the combination, subdivision or reclassification of the common stock. No fractional shares will be issued upon conversion. Payment of accumulated and unpaid dividends will be made upon conversion to the extent of legally-available funds. The shares of Preferred Stock may also be converted into common stock at the Conversion Rate at the Company’s option following the effectiveness of a Registration Statement, if the Company’s common stock trades above 200% of the Conversion Rate per share for a period of 20 consecutive trading days.
	Voting Rights
	The affirmative vote of the holders of at least two-thirds of the outstanding shares of Preferred Stock, voting as a class, shall be required to authorize, effect or validate (i) any change in the rights, privileges or preferences of the Preferred Stock that would adversely affect the Preferred Stock, or (ii) the authorization, creation, issuance or increase in the authorized or issued amount of any class or series of stock ranking on parity with or superior to the Preferred Stock with respect to the declaration and payment of dividends or distribution of assets upon liquidation, dissolution or winding-up of our Company. In addition, the holders of Preferred Stock shall have the right to vote, together with holders of common stock as single class, on all matters upon which the holders of common stock are entitled to vote pursuant to applicable Delaware law or the Company’s Certificate of Incorporation. The Preferred Stock shall vote on an “as converted basis” with each holder of Preferred Stock having one vote for each Conversion Share underlying such holder’s shares of Preferred Stock.
	Liquidation
	In the event of any voluntary or involuntary liquidation, dissolution or winding-up of the Company, before any payment or distribution of the assets of the Company (whether capital or surplus), or the proceeds thereof, may be made or set apart for the holders common stock or any stock ranking junior to Preferred Stock, the holders of Preferred Stock will be entitled to receive, out of the assets of the Company available for distribution to stockholders, a liquidating distribution of $1,000 per share, plus any accrued and unpaid dividends, subject to adjustment upon the occurrence of certain events. If, upon any voluntary or involuntary liquidation, dissolution or winding up of the Company, the assets of the Company are insufficient to make the full payment of $1,000 per share, plus all accrued and unpaid dividends on the Preferred Stock and similar payments on any other class of stock ranking on a parity with the Preferred Stock upon liquidation, then the holders of Preferred Stock and such other shares will share ratably in any such distribution of the Company’s assets in proportion to the full respective distributable amounts to which they are entitled. Certain events, including a consolidation or merger of the Company with or into another corporation or sale or conveyance of all or substantially all the property and assets of the Company will be deemed to be a liquidation, dissolution or winding-up of the Company for purposes of the foregoing.
	Series B Convertible Preferred Stock
	The Series B Convertible Preferred Stock (“Series B Preferred Stock”) has been authorized by resolutions adopted by the Company’s Board of Directors and set forth in a Certificate of Designation, Preferences and Rights (“Certificate of Designation”), filed with the Secretary of State of Delaware on September 2, 2011, which contains the designations, rights, powers, preferences, qualifications and limitations of the Series B Preferred Stock. The shares of Series B Preferred Stock are fully paid and non-assessable. As of September 30, 2014, the Company had issued 2,146 shares of Series B Preferred Stock convertible into an aggregate of 2,525,842 shares of common stock.
	Rank
	The Series B Preferred Stock ranks(i) senior to the common stock and any other class or series of the Company’s capital stock either specifically ranking by its terms junior to the Series B Preferred Stock or not specifically ranking by its terms senior to or on parity with the Series B Preferred Stock, (ii) on parity with any class or series of the Company’s capital stock specifically ranking by its terms on parity with the Series B Preferred Stock, and (iii) junior to Series A Preferred Stock, in each case, as to distributions of assets upon liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary.
	Dividends
	The holders of the Series B Preferred Stock are entitled to receive annual cumulative per share dividends of 6.5% of the liquidation preference of the Series B Preferred Stock, out of funds legally available, prior to any payment of dividends on the Company’s common stock or any other class of stock ranking junior to the Series B Preferred Stock. Such dividends are payable in cash or shares of common stock, at the option of the Company. The holders of the Series B Preferred Stock are entitled to share ratably with the holders of the common stock in any dividend declared on the common stock.
	Dividends on the Series B Preferred Stock will accrue whether or not the Company has earnings, whether or not there are funds legally available for the payment of such dividends and whether or not such dividends are declared. Dividends accumulate to the extent they are not paid on the Dividend Payment Date to which they relate. According to Delaware law, the Company may declare and pay dividends or make other distributions on its capital stock only out of legally-available funds. In addition, no dividends or distributions may be declared, paid or made if the Company is or would be rendered insolvent by virtue of such dividend or distribution. The Company may not (i) pay any dividends in respect of any shares of capital stock ranking junior to the Series B Preferred Stock (including the common stock), other than dividends payable in the form of additional shares of the same junior stock as that on which such dividend is declared, or (ii) redeem any shares of capital stock ranking junior to the Series B Preferred Stock (including the common stock), unless and until all accumulated and unpaid dividends on the Series B Preferred Stock have been, or contemporaneously are, declared and paid in full.
	Conversion
	At the election of the holder thereof, each share of Series B Preferred Stock will be convertible into common stock, at any time after issuance, at the Conversion Rate, as it may be adjusted from time to time in accordance with the Certificate of Designation. The Conversion Rate initially will be 1,177 shares of common stock ($.85 per share) for each Share of Series B Preferred Stock, which has a stated value of $1,000 per share.
	The Conversion Price is subject to adjustment from time to time in the event of (i) the issuance of common stock as a dividend or distribution on any class of the Company’s capital stock; or (ii) the combination, subdivision or reclassification of the common stock. No fractional shares will be issued upon conversion. Payment of accumulated and unpaid dividends will be made upon conversion to the extent of legally-available funds. The shares of Preferred Stock may also be converted into common stock at the Conversion Rate at the Company’s option following the effectiveness of a Registration Statement, if the Company’s common stock trades above 200% of the Conversion Rate per share for a period of 20 consecutive trading days.
	Voting Rights
	The affirmative vote of the holders of at least a majority of the outstanding shares of Preferred Stock, voting as a class, shall be required to authorize, effect or validate (i) any change in the rights, privileges or preferences of the Series B Preferred Stock that would adversely affect the Series B Preferred Stock, or (ii) the authorization, creation, issuance or increase in the authorized or issued amount of any class or series of stock ranking on parity with or superior to the Series B Preferred Stock with respect to the declaration and payment of dividends or distribution of assets upon liquidation, dissolution or winding-up of our Company. In addition, the holders of Preferred Stock shall have the right to vote, together with holders of common stock as single class, on all matters upon which the holders of common stock are entitled to vote pursuant to applicable Delaware law or the Company’s Certificate of Incorporation. The Series B Preferred Stock shall vote on an “as converted basis” with each holder of Preferred Stock having one vote for each Conversion Share underlying such holder’s shares of Preferred Stock.
	Liquidation
	In the event of any voluntary or involuntary liquidation, dissolution or winding-up of the Company, before any payment or distribution of the assets of the Company (whether capital or surplus), or the proceeds thereof, may be made or set apart for the holders common stock or any stock ranking junior to Preferred Stock, after payment to the holders of Series A Preferred Stock the holders of Preferred Stock will be entitled to receive, out of the assets of the Company available for distribution to stockholders, a liquidating distribution of $1,000 per share, plus any accrued and unpaid dividends, subject to adjustment upon the occurrence of certain events. If, upon any voluntary or involuntary liquidation, dissolution or winding up of the Company, the assets of the Company are insufficient to make the full payment of $1,000 per share, plus all accrued and unpaid dividends on the Preferred Stock and similar payments on any other class of stock ranking on a parity with the Preferred Stock upon liquidation, then the holders of Preferred Stock and such other shares will share ratably in any such distribution of the Company’s assets in proportion to the full respective distributable amounts to which they are entitled. Certain events, including a consolidation or merger of the Company with or into another corporation or sale or conveyance of all or substantially all the property and assets of the Company will be deemed to be a liquidation, dissolution or winding-up of the Company for purposes of the foregoing.
	Series C Convertible Preferred Stock
	The Series C Convertible Preferred Stock (“Series C Preferred Stock”) has been authorized by resolutions adopted by the Company’s Board of Directors and set forth in a Certificate of Designation, Preferences and Rights (“Certificate of Designation”), filed with the Secretary of State of Delaware on March 12, 2013, which contains the designations, rights, powers, preferences, qualifications and limitations of the Series C Preferred Stock. The shares of Series C Preferred Stock are fully paid and non-assessable. As of September 30, 2014, the Company had issued 5,000 shares of Series C Preferred Stock convertible into an aggregate of 4,000,000 shares of common stock.
	Rank
	The Series C Preferred Stock ranks(i) senior to the common stock and any other class or series of the Company’s capital stock either specifically ranking by its terms junior to the Series C Preferred Stock or not specifically ranking by its terms senior to or on parity with the Series C Preferred Stock, (ii) on parity with the Series B Preferred Stock and any class or series of the Company’s capital stock specifically ranking by its terms on parity with the Series C Preferred Stock, and (iii) junior to Series A Preferred Stock, in each case, as to distributions of assets upon liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary.
	Dividends
	The holders of the Series C Preferred Stock are entitled to receive annual cumulative per share dividends of 6.5% of the liquidation preference of the Series C Preferred Stock, out of funds legally available, prior to any payment of dividends on the Company’s common stock or any other class of stock ranking junior to the Series C Preferred Stock. Such dividends are payable in cash or shares of common stock, at the option of the Company. The holders of the Series C Preferred Stock are entitled to share ratably with the holders of the common stock in any dividend declared on the common stock.
	Dividends on the Series C Preferred Stock will accrue whether or not the Company has earnings, whether or not there are funds legally available for the payment of such dividends and whether or not such dividends are declared. Dividends accumulate to the extent they are not paid on the Dividend Payment Date to which they relate. According to Delaware law, the Company may declare and pay dividends or make other distributions on its capital stock only out of legally-available funds. In addition, no dividends or distributions may be declared, paid or made if the Company is or would be rendered insolvent by virtue of such dividend or distribution. The Company may not (i) pay any dividends in respect of any shares of capital stock ranking junior to the Series C Preferred Stock (including the common stock), other than dividends payable in the form of additional shares of the same junior stock as that on which such dividend is declared, or (ii) redeem any shares of capital stock ranking junior to the Series C Preferred Stock (including the common stock), unless and until all accumulated and unpaid dividends on the Series C Preferred Stock have been, or contemporaneously are, declared and paid in full.
	Conversion
	At the election of the holder thereof, each share of Series C Preferred Stock will be convertible into common stock, at any time after issuance, at the Conversion Rate, as it may be adjusted from time to time in accordance with the Certificate of Designation. The Conversion Rate initially will be 800 shares of common stock ($1.25 per share) for each Share of Series C Preferred Stock, which has a stated value of $1,000 per share.
	The Conversion Price is subject to adjustment from time to time in the event of (i) the issuance of common stock as a dividend or distribution on any class of the Company’s capital stock; or (ii) the combination, subdivision or reclassification of the common stock. No fractional shares will be issued upon conversion. Payment of accumulated and unpaid dividends will be made upon conversion to the extent of legally-available funds. The shares of Preferred Stock may also be converted into common stock at the Conversion Rate at the Company’s option following the effectiveness of a Registration Statement, if the Company’s common stock trades above 300% of the Conversion Rate per share for a period of 20 consecutive trading days.
	Voting Rights
	The affirmative vote of the holders of at least a majority of the outstanding shares of Preferred Stock, voting as a class, shall be required to authorize, effect or validate (i) any change in the rights, privileges or preferences of the Series C Preferred Stock that would adversely affect the Series C Preferred Stock, or (ii) the authorization, creation, issuance or increase in the authorized or issued amount of any class or series of stock ranking on parity with or superior to the Series C Preferred Stock with respect to the declaration and payment of dividends or distribution of assets upon liquidation, dissolution or winding-up of our Company. In addition, the holders of Preferred Stock shall have the right to vote, together with holders of common stock as single class, on all matters upon which the holders of common stock are entitled to vote pursuant to applicable Delaware law or the Company’s Certificate of Incorporation. The Series C Preferred Stock shall vote on an “as converted basis” with each holder of Preferred Stock having one vote for each Conversion Share underlying such holder’s shares of Preferred Stock.
	Liquidation
	In the event of any voluntary or involuntary liquidation, dissolution or winding-up of the Company, before any payment or distribution of the assets of the Company (whether capital or surplus), or the proceeds thereof, may be made or set apart for the holders common stock or any stock ranking junior to Preferred Stock, after payment to the holders of Series A Preferred Stock the holders of Preferred Stock will be entitled to receive, out of the assets of the Company available for distribution to stockholders, a liquidating distribution of $1,000 per share, plus any accrued and unpaid dividends, subject to adjustment upon the occurrence of certain events. If, upon any voluntary or involuntary liquidation, dissolution or winding up of the Company, the assets of the Company are insufficient to make the full payment of $1,000 per share, plus all accrued and unpaid dividends on the Preferred Stock and similar payments on any other class of stock ranking on a parity with the Preferred Stock upon liquidation, then the holders of Preferred Stock and such other shares will share ratably in any such distribution of the Company’s assets in proportion to the full respective distributable amounts to which they are entitled. Certain events, including a consolidation or merger of the Company with or into another corporation or sale or conveyance of all or substantially all the property and assets of the Company will be deemed to be a liquidation, dissolution or winding-up of the Company for purposes of the foregoing.
	Series D Convertible Preferred Stock
	The Series D Convertible Preferred Stock (“Series D Preferred Stock”) has been authorized by resolutions adopted by the Company’s Board of Directors and set forth in a Certificate of Designation, Preferences and Rights (“Certificate of Designation”), filed with the Secretary of State of Delaware on September 11, 2014, which contains the designations, rights, powers, preferences, qualifications and limitations of the Series D Preferred Stock. The shares of Series D Preferred Stock are fully paid and non-assessable. As of September 30, 2014, the Company has not issued any shares of Series D Preferred Stock convertible into an aggregate of 0 shares of common stock.
	Rank
	The Series D Preferred Stock ranks(i) senior to the common stock and any other class or series of the Company’s capital stock either specifically ranking by its terms junior to the Series D Preferred Stock or not specifically ranking by its terms senior to or on parity with the Series D Preferred Stock, (ii) on parity with the Series B and C Preferred Stock and any class or series of the Company’s capital stock specifically ranking by its terms on parity with the Series D Preferred Stock, and (iii) junior to Series A Preferred Stock, in each case, as to distributions of assets upon liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary.
	Dividends
	The holders of the Series D Preferred Stock are entitled to receive annual cumulative per share dividends of 6.5% of the liquidation preference of the Series D Preferred Stock, out of funds legally available, prior to any payment of dividends on the Company’s common stock or any other class of stock ranking junior to the Series D Preferred Stock. Such dividends are payable in cash or shares of common stock, at the option of the Company. The holders of the Series D Preferred Stock are entitled to share ratably with the holders of the common stock in any dividend declared on the common stock.
	Dividends on the Series D Preferred Stock will accrue whether or not the Company has earnings, whether or not there are funds legally available for the payment of such dividends and whether or not such dividends are declared. Dividends accumulate to the extent they are not paid on the Dividend Payment Date to which they relate. According to Delaware law, the Company may declare and pay dividends or make other distributions on its capital stock only out of legally-available funds. In addition, no dividends or distributions may be declared, paid or made if the Company is or would be rendered insolvent by virtue of such dividend or distribution. The Company may not (i) pay any dividends in respect of any shares of capital stock ranking junior to the Series D Preferred Stock (including the common stock), other than dividends payable in the form of additional shares of the same junior stock as that on which such dividend is declared, or (ii) redeem any shares of capital stock ranking junior to the Series D Preferred Stock (including the common stock), unless and until all accumulated and unpaid dividends on the Series D Preferred Stock have been, or contemporaneously are, declared and paid in full.
	Conversion
	At the election of the holder thereof, each share of Series D Preferred Stock will be convertible into common stock, at any time after issuance, at the Conversion Rate, as it may be adjusted from time to time in accordance with the Certificate of Designation. The Conversion Rate initially will be 500 shares of common stock ($2.00 per share) for each Share of Series D Preferred Stock, which has a stated value of $1,000 per share.
	The Conversion Price is subject to adjustment from time to time in the event of (i) the issuance of common stock as a dividend or distribution on any class of the Company’s capital stock; or (ii) the combination, subdivision or reclassification of the common stock. No fractional shares will be issued upon conversion. Payment of accumulated and unpaid dividends will be made upon conversion to the extent of legally-available funds. The shares of Preferred Stock may also be converted into common stock at the Conversion Rate at the Company’s option following the effectiveness of a Registration Statement, if the Company’s common stock trades above 300% of the Conversion Rate per share for a period of 20 consecutive trading days.
	Voting Rights
	The affirmative vote of the holders of at least a majority of the outstanding shares of Preferred Stock, voting as a class, shall be required to authorize, effect or validate (i) any change in the rights, privileges or preferences of the Series D Preferred Stock that would adversely affect the Series D Preferred Stock, or (ii) the authorization, creation, issuance or increase in the authorized or issued amount of any class or series of stock ranking on parity with or superior to the Series D Preferred Stock with respect to the declaration and payment of dividends or distribution of assets upon liquidation, dissolution or winding-up of our Company. In addition, the holders of Preferred Stock shall have the right to vote, together with holders of common stock as single class, on all matters upon which the holders of common stock are entitled to vote pursuant to applicable Delaware law or the Company’s Certificate of Incorporation. The Series D Preferred Stock shall vote on an “as converted basis” with each holder of Preferred Stock having one vote for each Conversion Share underlying such holder’s shares of Preferred Stock.
	Liquidation
	In the event of any voluntary or involuntary liquidation, dissolution or winding-up of the Company, before any payment or distribution of the assets of the Company (whether capital or surplus), or the proceeds thereof, may be made or set apart for the holders common stock or any stock ranking junior to Preferred Stock, after payment to the holders of Series A Preferred Stock the holders of Preferred Stock will be entitled to receive, out of the assets of the Company available for distribution to stockholders, a liquidating distribution of $1,000 per share, plus any accrued and unpaid dividends, subject to adjustment upon the occurrence of certain events. If, upon any voluntary or involuntary liquidation, dissolution or winding up of the Company, the assets of the Company are insufficient to make the full payment of $1,000 per share, plus all accrued and unpaid dividends on the Preferred Stock and similar payments on any other class of stock ranking on a parity with the Preferred Stock upon liquidation, then the holders of Preferred Stock and such other shares will share ratably in any such distribution of the Company’s assets in proportion to the full respective distributable amounts to which they are entitled. Certain events, including a consolidation or merger of the Company with or into another corporation or sale or conveyance of all or substantially all the property and assets of the Company will be deemed to be a liquidation, dissolution or winding-up of the Company for purposes of the foregoing.
	During the nine months ended September 30, 2014, the Company issued 1,621 shares of its par value $0.10 Series C Convertible Preferred Stock for cash at $1,000 per share.
	During the year ended December 31, 2013, the Company issued 3,380 shares of its par value, $0.10 Series C Convertible Preferred Stock for cash at $1,000 per share.
	As of September 30, 2014 and December 31, 2013, the Company has accrued $796,181 and $1,353,961 and has paid $1,025,404 and $0 dividends, respectively.

NOTE_9

NOTE 9	9 Months Ended
	Sep. 30, 2014
Notes
NOTE 9	NOTE 9 – COMMON STOCK
	During period ended September 30, 2014, the Company issued 40,000 shares of common stock to the Chairman of the Audit Committee for services for a value of $34,000. The Chairman of the Audit Committee received 30,000, 40,000 and 40,000 restricted shares of Common Stock on December 28, 2010, December 22, 2011 and February 20, 2013, in consideration of consulting and accounting services as chairman of the Company’s Audit Committee. The 40,000 issued during the period was valued at the stock price of $0.85. During the same period, the Company recorded a stock payable of $17,000 for services and will be issued to him after full year of service. He will be reimbursed for reasonable expenses incurred, however will not receive any other cash compensation.  The Company also settled $1,024,198 of accrued dividends payable by issuing 1,206,387 shares of common stock to Series A Preferred shareholders valued at $.85 per share.

NOTE_3_Use_of_Estimates_Polici

NOTE 3: Use of Estimates (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Policies
Use of Estimates	Use of Estimates	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

NOTE_3_Accounting_Basis_Polici

NOTE 3: Accounting Basis (Policies)	12 Months Ended
	Dec. 31, 2013
Policies
Accounting Basis	Accounting Basis
	The Company’s financial statements are prepared using the accrual basis of accounting in accordance with accounting principles generally accepted in the United States.  The Company has elected a December 31 fiscal year end.

NOTE_3_Cash_and_Cash_Equivalen

NOTE 3: Cash and Cash Equivalents (Policies)	12 Months Ended
	Dec. 31, 2013
Policies
Cash and Cash Equivalents	Cash and Cash Equivalents
	The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. There were no cash equivalents as of December 31, 2013 or 2012.

NOTE_3_Concentration_of_Credit

NOTE 3: Concentration of Credit Risk (Policies)	12 Months Ended
	Dec. 31, 2013
Policies
Concentration of Credit Risk	Concentration of Credit Risk
	Financial instruments, which potentially subject us to concentrations of credit risk, consist principally of cash.   Our cash balances are maintained in accounts held by major banks and financial institutions located in the United States.  The Company occasionally maintains amounts on deposit with a financial institution that are in excess of the federally insured limit of $250,000. The risk is managed by maintaining all deposits in high quality financial institutions. The Company had $991,397 and $0 of cash balances in excess of federally insured limits at December 31, 2013 and 2012, respectively.

NOTE_3_Property_and_Equipment_

NOTE 3: Property and Equipment (Policies)	12 Months Ended
	Dec. 31, 2013
Policies
Property and Equipment	Property and Equipment
	Property and equipment is recorded at cost less accumulated depreciation. Depreciation and amortization is calculated using the straight-line method over the expected useful life of the asset, after the asset is placed in service. The Company generally uses the following depreciable lives for its major classifications of property and equipment:
	Description	Useful Lives
	Computers	3 years
	Equipment	5 years

NOTE_3_Fair_Value_of_Financial

NOTE 3: Fair Value of Financial Instruments (Policies)	9 Months Ended									12 Months Ended
	Sep. 30, 2014									Dec. 31, 2013
Policies
Fair Value of Financial Instruments	Fair Value of Financial Instruments									Fair Value of Financial Instruments
	In accordance with ASC 820, the carrying value of cash and cash equivalents, accounts receivable and accounts payable approximates fair value due to the short-term maturity of these instruments. ASC 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:									In accordance with ASC 820, the carrying value of cash and cash equivalents, accounts receivable and accounts payable approximates fair value due to the short-term maturity of these instruments.  ASC 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:
	Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.									Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.
	Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.									Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.
	Level 3-Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.									Level 3-Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.
	The carrying amounts reported in the balance sheets for cash, accounts payable and accrued expenses, approximate their fair market value based on the short-term maturity of these instruments. The following table presents assets and liabilities that are measured and recognized at fair value as of September 30, 2014, on a recurring basis:									The carrying amounts reported in the balance sheets for cash, accounts payable and accrued expenses approximate their fair market value based on the short-term maturity of these instruments. The following table presents assets and liabilities that are measured and recognized at fair value as of December 31, 2013, on a recurring basis:
	Description	Level 1		Level 2		Level 3		Gains (Losses)		Description		Level 1		Level 2		Level 3		Total
										Derivative Liability		$	-	$	-	$	-	$	-
		$	-	$	-	$	-	$	-	Total		$	-	$	-	$	-	$	-
	Total	$	-	$	-	$	-	$	-
										The following table presents assets and liabilities that are measured and recognized at fair value as of December 31, 2012, on a recurring basis:
	The following table presents assets and liabilities that are measured and recognized at fair value as of December 31, 2013, on a recurring basis:
										Description		Level 1		Level 2		Level 3		Total
	Description	Level 1		Level 2		Level 3		Gains (Losses)		Derivative Liability		$	-	$	-	$	-5,687,262	$	-5,687,262
										Total		$	-	$	-	$	-5,687,262	$	-5,687,262
		$	-	$	-	$	-	$	-
	Total	$	-	$	-	$	-	$	-	A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The following is a description of the valuation methodology used to measure fair value, as well as the general classification of such instruments pursuant to the valuation hierarchy.
	A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The following is a description of the valuation methodology used to measure fair value, as well as the general classification of such instruments pursuant to the valuation hierarchy.									Derivative Liability:     Market prices are not available for the Company's warrants nor are market prices of similar warrants available. The Company assessed that the fair value of this liability approximates its carrying value since carrying value has been adjusted to fair value.
										The method described above may produce a current fair value calculation that may not be indicative of net realizable value or reflective of future fair values. If a readily determined market value became available or if actual performance were to vary appreciably from assumptions used, assumptions may need to be adjusted, which could result in material differences from the recorded carrying amounts. The Company believes its method of determining fair value is appropriate and consistent with other market participants. However, the use of different methodologies or different assumptions to value certain financial instruments could result in a different estimate of fair value.
										The following tables present the fair value of financial instruments as of December 31, 2013, by caption on the condensed balance sheet and by ASC 820 valuation hierarchy described above.
											Stock Warrant
										Level 3 Reconciliation:	Derivative
										Level 3 assets and liabilities at December 31, 2012	$	-5,687,262
										Purchases, sales, issuances and settlements (net)		5,687,262
										Total level 3 assets and liabilities at December 31, 2013	$	-

NOTE_3_Derivative_Financial_In

NOTE 3: Derivative Financial Instruments (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Policies
Derivative Financial Instruments	Derivative Financial Instruments	Derivative Financial Instruments
	The Company generally does not use derivative financial instruments to hedge exposures to cash-flow risks or market-risks that may affect the fair values of its financial instruments. The Company utilizes various types of financing to fund our business needs, including preferred stock with warrants attached and other instruments not indexed to our stock. The Company is required to record its derivative instruments at their fair value. Changes in the fair value of derivatives are recognized in earnings in accordance with ASC 815.	The Company generally does not use derivative financial instruments to hedge exposures to cash-flow risks or market-risks that may affect the fair values of its financial instruments. The Company utilizes various types of financing to fund our business needs, including preferred stock with warrants attached and other instruments not indexed to our stock. The Company is required to record its derivative instruments at their fair value. Changes in the fair value of derivatives are recognized in earnings in accordance with ASC 815.

NOTE_3_Research_and_Developmen

NOTE 3: Research and Development Costs (Policies)	12 Months Ended
	Dec. 31, 2013
Policies
Research and Development Costs	Research and Development Costs
	The Company expenses the costs of the development of its pharmaceutical products during the period incurred. The Company incurred research and development expenses of $841,502 and $939,296 during the years ended December 31, 2013 and 2012, respectively.

NOTE_3_Stockbased_Compensation

NOTE 3: Stock-based Compensation (Policies)	12 Months Ended
	Dec. 31, 2013
Policies
Stock-based Compensation	Stock-Based Compensation
	The Company follows the provisions of ASC 718 which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values.  The Company uses the Black-Scholes pricing model for determining the fair value of stock based compensation.
	Equity instruments issued to non-employees for goods or services are accounted for at fair value and are marked to market until service is complete or a performance commitment date is reached, whichever is earlier.

NOTE_3_Income_Taxes_Policies

NOTE 3: Income Taxes (Policies)	12 Months Ended
	Dec. 31, 2013
Policies
Income Taxes	Income Taxes
	The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.
	In July, 2006, the FASB issued ASC 740, Accounting for Uncertainty in Income Taxes, which clarifies the accounting for uncertainty in tax positions taken or expected to be taken in a return. ASC 740 provides guidance on the measurement, recognition, classification and disclosure of tax positions, along with accounting for the related interest and penalties. ASC 740 became effective as of January 1, 2007 and had no impact on the Company’s financial statements.
	The charge for taxation is based on the results for the year as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.

NOTE_3_Basic_and_Diluted_Net_I

NOTE 3: Basic and Diluted Net Income (loss) Per Share (Policies)	12 Months Ended
	Dec. 31, 2013
Policies
Basic and Diluted Net Income (loss) Per Share	Basic and Diluted Net income (Loss) per Share
	The Company computes net income (loss) per share in accordance with ASC 260 which requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive.
	For the years ended December 31, 2013 and 2012, all of the Company’s potentially dilutive securities (warrants, options, and convertible preferred stock) were excluded from the computation of diluted earnings per share as they were anti-dilutive.  The total number of potentially dilutive shares that were excluded was 18,162,608 and 12,814,874 at December 31, 2013 and 2012, respectively.

NOTE_3_Recent_Accounting_Prono

NOTE 3: Recent Accounting Pronouncements (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Policies
Recent Accounting Pronouncements	Recent Accounting Pronouncements	Recent Accounting Pronouncements
	The Company has evaluated recent accounting pronouncements and their adoption has not had nor is it expected to have a material impact on the Company’s financial position, or statements.	The Company has evaluated recent accounting pronouncements and their adoption has not had nor is it expected to have a material impact on the Company’s financial position, or statements.
	In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-10, “Development Stage Entities”. The amendments in this update remove the definition of a development stage entity from the Master Glossary of the ASC thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP.  In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had` been in the development stage. The amendments in this update are applied retrospectively. The early adoption of ASU 2014-10 is permitted which removed the development stage entity financial reporting requirements from the Company.

NOTE_3_Fair_Value_of_Financial1

NOTE 3: Fair Value of Financial Instruments: Fair Value, Liabilities Measured on Recurring Basis (Tables)	12 Months Ended
	Dec. 31, 2013
Tables/Schedules
Fair Value, Liabilities Measured on Recurring Basis
	Description	Level 1		Level 2		Level 3		Total
	Derivative Liability	$	-	$	-	$	-	$	-
	Total	$	-	$	-	$	-	$	-
	The following table presents assets and liabilities that are measured and recognized at fair value as of December 31, 2012, on a recurring basis:
	Description	Level 1		Level 2		Level 3		Total
	Derivative Liability	$	-	$	-	$	-5,687,262	$	-5,687,262
	Total	$	-	$	-	$	-5,687,262	$	-5,687,262

NOTE_3_Fair_Value_of_Financial2

NOTE 3: Fair Value of Financial Instruments: Level 3 Valuation Reconciliation (Tables)	12 Months Ended
	Dec. 31, 2013
Tables/Schedules
Level 3 Valuation Reconciliation
		Stock Warrant
	Level 3 Reconciliation:	Derivative
	Level 3 assets and liabilities at December 31, 2012	$	-5,687,262
	Purchases, sales, issuances and settlements (net)		5,687,262
	Total level 3 assets and liabilities at December 31, 2013	$	-

NOTE_4_Property_Plant_and_Equi

NOTE 4: Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Tables/Schedules
Property, Plant and Equipment
		2013		2012
	Computer equipment	$	5,390	$	5,390
	Accumulated Depreciation		-5,390		-5,246
	Net Book Value	$	-	$	144

NOTE_7_Fair_value_of_the_prefe

NOTE 7: Fair value of the preferred stock (Tables)	12 Months Ended
	Dec. 31, 2013
Tables/Schedules
Fair value of the preferred stock
	Balance, December 31, 2012	$	5,687,262
	Derivative loss		3,923
	Derivative liability for warrants removed during the period		-5,691,185
	Balance, December 31, 2013	$	-

WARRANTS_Schedule_of_Stockhold

WARRANTS: Schedule of Stockholders' Equity Note, Warrants or Rights (Tables)	9 Months Ended					12 Months Ended
	Sep. 30, 2014					Dec. 31, 2013
Tables/Schedules
Schedule of Stockholders' Equity Note, Warrants or Rights
	Date of	Warrant	Exercise		Value if	Date of	Warrant	Exercise	Value if
	Issuance	Shares	Price		Exercised	Issuance	Shares	Price	Exercised
	Outstanding at 12/31/13	12,792,728	1.18		15,065,087	11/25/08	1,259,639	1.27	$         1,599,742
	3/21/14	20,200	1.85		37,370	11/25/08	530,314	0.85	450,767
	3/21/14	50,000	1.85		92,500	11/26/08	449,220	1.27	570,509
	3/21/14	40,000	1.85		74,000	Outstanding at 12/31/2008	2,239,173	1.17	2,621,018
	3/21/14	40,000	1.85		74,000	3/5/09	347,215	1.27	440,963
	3/21/14	90,120	1.25		112,650	3/5/09	104,165	0.85	88,540
	5/5/14	4,000	1.88		7,520	4/1/09	17,655	1.27	22,422
	5/5/14	236,000	1.88		443,680	4/1/09	5,296	0.85	4,502
	5/5/14	144,000	1.25		180,000	6/17/09	235,400	1.27	298,958
	5/28/14	1,484,851	1.25		1,856,064	6/17/09	70,620	0.85	60,027
	5/28/14	(1,537,840)	1.25		(1,922,300)	7/23/09	58,850	1.27	74,740
	6/18/14	190,000	1.88		357,200	7/23/09	35,310	0.85	30,014
	6/18/14	16,000	1.88		30,080	8/20/09	58,850	1.27	74,740
	6/18/14	47,800	1.88		89,864	9/9/09	235,400	1.27	298,958
	6/18/14	4,000	1.88		7,520	9/9/09	70,620	0.85	60,027
	6/18/14	154,680	1.25		193,350	Outstanding at 12/31/2009	3,478,554	1.17	4,074,909
	7/22/14	(1,484,851)	1.25		(1,856,064)	2/11/10	29,425	1.27	37,370
	7/22/14	1,469,851	1.25		1,837,314	2/11/10	17,655	0.85	15,007
	7/22/14	15,000	1.25		18,750	5/21/10	29,425	1.27	37,370
	7/22/14	(607,200)	.85		(516,120)	5/21/10	17,655	0.85	15,007
	7/22/14	607,200	.85		516,120	8/10/10	88,275	1.27	112,109
	Outstanding at 9/30/14	13,776,539	1.43	$	19,673,118	8/10/10	52,965	0.85	45,020
						9/15/10	264,825	1.27	336,328
						9/15/10	52,965	0.85	45,020
						9/24/10	105,930	0.85	90,041
						10/27/10	147,125	1.27	186,849
						10/27/10	73,563	0.85	62,529
						11/19/10	117,700	1.27	149,479
						11/24/10	70,620	0.85	60,027
						Outstanding at 12/31/2010	4,546,682	1.16	5,267,063
						1/26/11	117,700	1.27	149,479
						1/26/11	60,027	1.27	76,234
						1/26/11	106,636	0.85	90,641
						3/15/11	58,850	1.27	74,740
						3/15/11	35,310	0.85	30,014
						4/6/11	70,620	0.85	60,027
						4/6/11	117,700	1.27	149,479
						6/8/11	51,200	0.85	43,520
						6/8/11	85,333	1.27	108,373
						6/20/11	17,655	0.85	15,007
						6/20/11	29,425	1.27	37,370
						7/26/11	23,540	1.27	29,896
						7/26/11	14,124	0.85	12,005
						8/22/11	29,424	1.27	37,368
						8/22/11	17,655	0.85	15,007
						8/30/11	105,930	0.85	90,041
						9/2/11	176,550	1.27	224,219
						9/9/11	58,850	1.27	74,740
						9/9/11	35,310	0.85	30,014
						9/22/11	441,375	1.27	560,546
						9/22/11	264,825	0.85	225,101
						11/2/11	141,240	0.85	120,054
						11/2/11	235,400	1.27	298,958
						11/23/11	35,310	0.85	30,014
						11/23/11	58,850	1.27	74,740
						12/27/11	127,116	0.85	108,049
						12/27/11	211,860	1.27	269,062
						Outstanding at 12/31/11	7,274,497	1.14	8,301,757
						1/31/12	117,700	1.27	149,479
						1/31/12	70,620	0.85	60,027
						2/2/12	76,505	1.27	97,161
					2/2/12	45,903	0.85	39,018
					2/10/12	58,850	1.27	74,740
					2/10/12	35,310	0.85	30,014
					4/10/12	41,666	0.85	35,416
					4/10/12	69,443	1.27	88,193
					5/11/12	35,310	0.85	30,014
					5/11/12	58,850	1.27	74,740
					6/4/12	35,310	0.85	30,014
					6/4/12	58,850	1.27	74,740
					6/19/12	35,310	0.85	30,014
					6/19/12	58,850	1.27	74,740
					7/24/12	44,138	1.27	56,055
					7/24/12	58,850	1.27	74,740
					7/24/12	30,896	0.85	26,262
					7/30/12	235,400	1.27	298,958
					7/30/12	141,240	0.85	120,054
					8/28/12	258,352	1.27	328,107
					8/28/12	155,011	0.85	131,759
					10/18/12	158,895	1.27	201,797
					10/18/12	95,337	0.85	81,036
					11/26/12	58,850	1.27	74,740
					11/27/12	35,310	0.85	30,014
					Outstanding at 12/31/12	9,345,253	1.14	10,613,584
					2/28/13	400,000	0.85	340,000
					3/1/13	(1,625,192)	0.85	(1,381,413)
					3/1/13	1,625,192	0.85	1,381,413
					3/13/13	800,000	1.88	1,500,000
					3/13/13	480,000	0.85	408,000
					6/19/13	127,200	0.85	108,120
					6/19/13	212,000	1.88	397,500
					7/24/13	60,000	1.88	112,500
					7/24/13	100,000	1.88	187,500
					7/24/13	96,000	1.25	120,000
					8/29/13	80,000	1.88	150,000
					8/29/13	48,000	1.25	60,000
					8/29/13	(48,000)	1.25	(60,000)
					10/24/13	61,764	0.85	52,499
					10/24/13	10,588	0.85	9,000
					10/24/13	1,552,840	0.85	1,319,914
					10/24/13	(1,552,840)	0.85	(1,319,914)
					10/24/13	10,000	1.25	12,500
					10/24/13	38,000	1.25	47,500
					11/8/13	100,000	1.88	187,500
					11/8/13	60,000	1.25	75,000
					12/18/13	78,000	1.25	97,500
					12/18/13	78,000	1.25	97,500
					12/18/13	15,000	0.85	12,750
					12/18/13	1,537,840	0.85	1,307,164
					Outstanding at 12/31/13	13,689,648	1.13	15,849,164

NOTE_11_Schedule_of_Deferred_T

NOTE 11: Schedule of Deferred Tax Assets and Liabilities (Tables)	12 Months Ended
	Dec. 31, 2013
Tables/Schedules
Schedule of Deferred Tax Assets and Liabilities
		2013		2012
	Cumulative NOL	$	7,436,707	$	6,185,210
	Deferred Tax assets:
	Net operating loss carry forwards		2,900,316		2,412,232
	Valuation allowance		-2,900,316		-2,412,232
		$	-	$	-

NOTE_11_Schedule_of_Effective_

NOTE 11: Schedule of Effective Income Tax Rate Reconciliation (Tables)	12 Months Ended
	Dec. 31, 2013
Tables/Schedules
Schedule of Effective Income Tax Rate Reconciliation
		2013		2012
	Income tax benefit at U. S. federal statutory rates:	$	-763,180	$	-511,264
	Stock-based compensation		273,565		9,027
	Derivative liability		1,531		3,180
	Change in valuation allowance		488,084		499,057
		$	-	$	-

NOTE_3_Fair_Value_of_Financial3

NOTE 3: Fair Value of Financial Instruments: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Tables)	9 Months Ended
	Sep. 30, 2014
Tables/Schedules
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
	Description	Level 1		Level 2		Level 3		Gains (Losses)
		$	-	$	-	$	-	$	-
	Total	$	-	$	-	$	-	$	-
	The following table presents assets and liabilities that are measured and recognized at fair value as of December 31, 2013, on a recurring basis:
	Description	Level 1		Level 2		Level 3		Gains (Losses)
		$	-	$	-	$	-	$	-
	Total	$	-	$	-	$	-	$	-

NOTE_4_Schedule_Of_Property_An

NOTE 4: Schedule Of Property And Equipment (Tables)	9 Months Ended
	Sep. 30, 2014
Tables/Schedules
Schedule Of Property And Equipment
		September 30,			December 31,
		2014			2013
	Computer equipment		$	5,390		$	5,390
	Accumulated Depreciation			-5,390			-5,390
	Net Book Value		$	-		$	-

NOTE_1_Details

NOTE 1 (Details)	12 Months Ended
	Dec. 31, 2013
Details
Entity Incorporation, State Country Name	Delaware
Entity Incorporation, Date of Incorporation	15-May-06

NOTE_2_Details

NOTE 2 (Details) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended							92 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2007	Dec. 31, 2013
Details
REVENUES
Net loss	982,790	489,305	2,139,679	1,671,998	1,956,872	1,310,934	2,284,393	2,119,059	730,743	1,695,766	526,833	10,668,408
Deficit accumulated during the development stage	12,808,087		12,808,087		10,668,408	8,711,536						10,668,408
Net loss	($982,790)	($489,305)	($2,139,679)	($1,671,998)	($1,956,872)	($1,310,934)	($2,284,393)	($2,119,059)	($730,743)	($1,695,766)	($526,833)	($10,668,408)

NOTE_3_Concentration_of_Credit1

NOTE 3: Concentration of Credit Risk (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Details
Cash balance in excess of federally insured limit	$991,397	$0

NOTE_3_Fair_Value_of_Financial4

NOTE 3: Fair Value of Financial Instruments: Fair Value, Liabilities Measured on Recurring Basis (Details) (USD $)	Dec. 31, 2012
Derivative Liability, Fair Value, Gross Asset	($5,687,262)
Derivative Liability, Fair Value, Amount Not Offset Against Collateral	-5,687,262
Fair Value, Inputs, Level 3
Derivative Liability, Fair Value, Gross Asset	-5,687,262
Derivative Liability, Fair Value, Amount Not Offset Against Collateral	($5,687,262)

NOTE_3_Fair_Value_of_Financial5

NOTE 3: Fair Value of Financial Instruments: Level 3 Valuation Reconciliation (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Details
Derivative liability		($5,687,262)
Purchases, sales, issuances and settlements (net)	$5,687,262

NOTE_3_Research_and_Developmen1

NOTE 3: Research and Development Costs (Details) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended		92 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Details
Research and development	$799,965	$312,671	$1,546,500	$618,739	$841,502	$939,296	$4,297,433

NOTE_3_Basic_and_Diluted_Net_I1

NOTE 3: Basic and Diluted Net Income (loss) Per Share (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Details
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	18,162,608	12,814,874

NOTE_3_Details

NOTE 3 (Details) (USD $)	12 Months Ended	92 Months Ended
	Dec. 31, 2013	Dec. 31, 2013
Details
DEEMED DIVIDEND ON WARRANTS	$2,445,621	$2,445,621

NOTE_4_Details

NOTE 4 (Details) (USD $)	9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Details
Depreciation expense		$144	$144	$1,265
Depreciation Expense	$0		$0

NOTE_4_Property_Plant_and_Equi1

NOTE 4: Property, Plant and Equipment (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Details
Property, Plant and Equipment, Gross	$5,390	$5,390	$5,390
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Excluding Capital Leased Assets	-5,390	-5,390	-5,246
EQUIPMENT, net			$144

NOTE_5_Details

NOTE 5 (Details) (USD $)	12 Months Ended
	Dec. 31, 2009	Sep. 30, 2014	Dec. 31, 2013	Apr. 07, 2009
Details
Probable liquidated damages		$85,738	$85,738
Liquidated damages				1,800,000	[1]
Liquid Damages 2 Percent of Gross Proceeds				$1,800,000
Holder Entitled Price Per Share	$47.32
Liquidated Damages Payment Per Share Amount	$1
[1]	December 31, 2009, the Company's registration statement covering the securities was declared effective by the SEC. Each holder is entitled to $47.32 per share owned. The Company has resolved to pay the liquidated damages in shares of Common Stock valued at $1.00 per share, pursuant to the terms and provisions of the Certificate of Designation, Preferences and Rights of Series A Convertible Preferred Stock.

NOTE_6_Details

NOTE 6 (Details) (USD $)	1 Months Ended				9 Months Ended	12 Months Ended
	Mar. 31, 2013		Jan. 31, 2013		Sep. 30, 2013	Dec. 31, 2013
Details
Proceeds from Unsecured Notes Payable						$55,075	[1]
Proceeds from related party notes payable	5,000	[2]	25,000	[2]	-30,000	30,000
Related Party Transaction, Amounts of Transaction	$5,000		$25,000
[1]	As of December 31, 2012, the balance on the note has been paid in full.
[2]	In April 2013, the balance on the note was repaid in full.

NOTE_7_Details

NOTE 7 (Details) (USD $)	9 Months Ended		12 Months Ended					92 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2013
Warrants Reclassified to Derivative Liabilties							3,572,714
Cumulative effect of adoption of ASC 815							$1,676,633
Gain (loss) on derivative liability	0	-3,926	-3,926	-8,154				-998,403
Warrants Issued Attached to Preferred Stock				1,313,533	1,704,884	676,775	953,370
Convertible Preferred Stock				1,116	1,449	575	810
Additional Warrants Issued as Stock Offering				757,223	1,022,931	391,353	286,011
Derivative Liability, Fair Value, Gross Liability				301,800	2,184,753	852,346	988,552
Mandatorily Redeemable Preferred Stock, Fair Value Disclosure			0	3,182,380				0
Warrants Fair Value			0	2,504,879				0
Gain (loss) on derivative liability	0	3,926	3,926	8,154				998,403
Deficit Accumulated During the Development Stage
Cumulative effect of adoption of ASC 815							$43,808
Minimum
Investment Warrants, Exercise Price			$0.85
Maximum
Investment Warrants, Exercise Price			$1.27

NOTE_7_Fair_value_of_the_prefe1

NOTE 7: Fair value of the preferred stock (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Details
Derivative Liability Balance Level 3		$5,687,262
Derivative, Loss on Derivative	3,923
Stock And Warrants Removed During Period Value Preferred Stock And Warrants	($5,691,185)

WARRANTS_Details

WARRANTS (Details) (USD $)	9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Feb. 20, 2013
Modification Expense			$156,477
Stock offering costs paid	247,464	510,476	550,326	221,175
Related party note payable	796,181		1,353,961	861,872
Class A Warrants Extended			3,226,032
Gain (Loss) on Sale of Equity Investments			156,477
Warrants Issued to Vendor					400,000
Warrants Issued to Vendor Exercise Price					$0.85
Warrants As Stock Offering Costs To Placement Agent	403,800		1,087,552
WarrantsasstockofferingcoststoplacementagentMember
Stock offering costs paid	$247,464	$404,151

STOCK_OPTIONS_Details

STOCK OPTIONS (Details) (USD $)	9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2012	Dec. 31, 2013	Dec. 31, 2012	Feb. 20, 2013	Jul. 12, 2010	1-May-14
Amortization of ESOP Award			$667,449	$16,772
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options	1,047,000
Authorized Increase Of Number Of Authorized Options	1,000,000
Authorized Increase Percentage Of Authorized Options	10.00%
Expense related to options	186,385	650,025
Stock Options 1
Options issued to a director					60,000	100,000
Black-Scholes option pricing model assumptions			$0.85 stock price, $1.25 exercise price, 5 years to maturity, 649% volatility, .35% risk free rate.	$0.85 stock price, 10 years to maturity, 400% volatility, 2.02% risk free rate.
Amortization of ESOP Award			4,952	16,772
Stock Options 2
Options issued to a director					60,000
Black-Scholes option pricing model assumptions			$0.85 stock price, $1.25 exercise price, 5 years to maturity, 649% volatility, .35% risk free rate.
Amortization of ESOP Award			50,928
Stock Options 3
Options issued to a director					60,000
Black-Scholes option pricing model assumptions			$0.85 stock price, $1.25 exercise price, 5 years to maturity, 649% volatility, .35% risk free rate.
Amortization of ESOP Award			50,941
Stock Options 4
Options issued to a director					60,000
Black-Scholes option pricing model assumptions			$0.85 stock price, $1.25 exercise price, 5 years to maturity, 649% volatility, .35% risk free rate.
Amortization of ESOP Award			50,928
Stock Options 5
Black-Scholes option pricing model assumptions			$0.85 stock price, $0.85 exercise price, 5 years to maturity, 649% volatility, .35% risk free rate.
Amortization of ESOP Award			50,928
Stock Options 6
Options issued to a director					82,400
Black-Scholes option pricing model assumptions			$0.85 stock price, $0.85 exercise price, 5 years to maturity, 626% volatility, .35% risk free rate.
Amortization of ESOP Award			69,918
Stock Options 7
Options issued to a director					117,600
Black-Scholes option pricing model assumptions			$0.85 stock price, $0.85 exercise price, 5 years to maturity, 626% volatility, .35% risk free rate.
Amortization of ESOP Award			99,786
Stock Options 8
Options issued to a director					30,000
Black-Scholes option pricing model assumptions			$0.85 stock price, $0.85 exercise price, 5 years to maturity, 885% volatility, .88% risk free rate.
Amortization of ESOP Award			$25,471
Options issued to the Company's law firm					30,000
StockOptions9Member
Options issued to a director							30,000
Black-Scholes option pricing model assumptions	$0.85 stock price, $1.25 exercise price, 5 years to maturity, 305% volatility, .64% risk free rate
StockOptions10Member
Options issued to a director							30,000
Black-Scholes option pricing model assumptions	$0.85 stock price, $1.25 exercise price, 5 years to maturity, 305% volatility, .64% risk free rate
StockOptions11Member
Options issued to a director							200,000
Black-Scholes option pricing model assumptions	$0.85 stock price, $1.25 exercise price, 5 years to maturity, 415.87% volatility, 1.66% risk free rate.

NOTE_11_Details

NOTE 11 (Details) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended		92 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Details
Provision for income taxes
Marginal tax rate					39.00%

NOTE_11_Schedule_of_Deferred_T1

NOTE 11: Schedule of Deferred Tax Assets and Liabilities (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Details
Operating Loss Carryforwards	$7,436,707	$6,185,210
Deferred Tax Assets, Operating Loss Carryforwards	2,900,316	2,412,232
Operating Loss Carryforwards, Valuation Allowance	($2,900,316)	($2,412,232)

NOTE_11_Schedule_of_Effective_1

NOTE 11: Schedule of Effective Income Tax Rate Reconciliation (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Details
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount	($763,180)	($511,264)
Share-based Compensation	273,565	9,027
Derivative liability Income tax	1,531	3,180
Valuation Allowance, Deferred Tax Asset, Change in Amount	$488,084	$499,057

NOTE_12_Details

NOTE 12 (Details) (USD $)	1 Months Ended				9 Months Ended	12 Months Ended
	Mar. 31, 2013		Jan. 31, 2013		Sep. 30, 2013	Dec. 31, 2013
Details
Proceeds from related party notes payable	$5,000	[1]	$25,000	[1]	($30,000)	$30,000
Repayment of related party notes payable						$30,000
[1]	In April 2013, the balance on the note was repaid in full.

NOTE_3_Fair_Value_of_Financial6

NOTE 3: Fair Value of Financial Instruments: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) (USD $)	Dec. 31, 2012
Details
Derivative Liability, Fair Value, Amount Not Offset Against Collateral	$5,687,262

NOTE_4_Schedule_Of_Property_An1

NOTE 4: Schedule Of Property And Equipment (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Details
Property, Plant and Equipment, Gross	$5,390	$5,390	$5,390
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Excluding Capital Leased Assets	-5,390	-5,390	-5,246
EQUIPMENT, net			$144

NOTE_8_Details

NOTE 8 (Details) (USD $)	9 Months Ended		12 Months Ended
	Sep. 30, 2014		Dec. 31, 2013		Dec. 31, 2012
Details
Series A Preferred Stock Issued	3,255
Series A Preferred Stock Issued - Aggregate	3,831,576
Series A Initial Conversion Rate Shares of Common Stock	1,177
Series B Preferred Stock Issued	2,146
Series B Preferred Stock Issued - Aggregate	2,525,842
Series B Initial Conversion Rate Shares of Common Stock	1,177
Series C Preferred Stock Issued	5,000
Series C Preferred Stock Issued - Aggregate	4,000,000
Series C Initial Conversion Rate Shares of Common Stock	800
Convertible Preferred Stock Series C Issued	1,621	[1],[2],[3]	3,380	[1],[2],[3]
Accrued dividends	$796,181		$1,353,961		$861,872
Stock Issued During Period, Value, Stock Dividend	$1,025,404		$0
[1]	par value $0.10
[2]	Series C
[3]	$1,000 per share

NOTE_9_Details

NOTE 9 (Details) (USD $)	3 Months Ended		9 Months Ended
	Apr. 15, 2008		Sep. 30, 2014	Feb. 20, 2013	Dec. 22, 2011	Dec. 28, 2010
Details
Common Stock Issued	1,082,500	[1]	40,000
Common Stock Issued - Value			$34,000
Restricted Shares Common Stock Issued				40,000	40,000	30,000
Stock Payable			17,000
Accrued Dividends Payable Settled with Issuance of Common Stock			$1,024,198
Common Stock Issued to Settle Accrued Dividends Payable			1,206,387
[1]	$0.85 per common share

WARRANTS_Schedule_of_Stockhold1

WARRANTS: Schedule of Stockholders' Equity Note, Warrants or Rights (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Details
Class of Warrant or Right, Outstanding	13,776,539	12,792,728
Warrant Exercise Price	$1.43	$1.18
Warrants and Rights Outstanding	$19,673,118	$15,065,087